Pyrimidine-containing tricyclic fused ring derivative inhibitor as well as preparation method and application thereof

Abstract

The invention relates to a pyrimidine-containing tricyclic fused ring derivative inhibitor as well as a preparation method and application thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method thereof, a pharmaceutical composition containing the compound, and uses thereof in treatment of cancers and other related diseases.

Description

Technical Field

[0001] This invention belongs to the field of drug synthesis, specifically relating to a pyrimidine tricyclic fused-ring derivative inhibitor, its preparation method, and its application. Background Technology

[0002] Rat sarcoma (RAS) proteins are encoded by the proto-oncogenes HRAS, NRAS, and KRAS, and consist of four proteins: HRAS, NRAS, KRAS4A, and KRAS4B. These proteins are GTP (guanosine triphosphate) binding proteins. RAS is located on the inner surface of the cell membrane, upstream of which is the receptor tyrosine kinase (RTK). Activation of RAS regulates downstream signaling pathways such as PI3K and RAF, thereby controlling cell growth, survival, migration, and differentiation.

[0003] RAS exists in two main states in the body: an inactive state bound to GDP (guanosine diphosphate) and an activated state bound to GTP. Its activity is regulated by two proteins: guanine nucleotide exchange factor (GEF) promotes the release of GDP from the RAS protein, enabling GTP binding and activation of RAS; GTPase activating protein (GAP) activates the GTPase activity of the RAS protein, hydrolyzing the GTP bound to RAS protein into GDP, thus inactivating RAS. Under normal circumstances, the RAS protein is in an inactive state. Mutations alter its conformation, leading to a persistently activated RAS state, and downstream signaling pathways are also continuously activated, resulting in the development of various cancers.

[0004] RAS was the first oncogene to be identified and also the most frequently mutated oncogene, accounting for an average of 25% of human cancers. The most common oncogene mutation in the RAS family is KRAS (85%), while NRAS (12%) and HRAS (3%) are less common. KRAS mutations are prevalent in a range of cancers, including pancreatic cancer (95%), colorectal cancer (52%), and lung cancer (31%). The most common type of KRAS mutation is point mutation, occurring primarily in the G12, G13, and Q61 regions (aa59-76) of the p-loop (aa 10-17), with G12 mutations being the most common (83%). Epidemiological studies in Europe and the United States show that KRAS G12D is the most common pathogenic mutation in pancreatic cancer, colorectal cancer, endometrial cancer, and lung cancer, with incidence rates of 36%, 12%, 6%, and 4%, respectively.

[0005] Despite significant clinical need, no drugs directly targeting KRAS have yet been marketed. Currently, chemotherapy is the only treatment option for patients with KRAS mutations. The difficulty in developing KRAS inhibitors stems from two main factors: firstly, the smooth structure of the RAS protein makes it difficult for small molecules to bind to its surface; secondly, the RAS GTPase has a high affinity for GTP at the picomolar (pM) level, and high levels of endogenous GTP make it difficult for small molecule drugs to block this binding. Currently, no KRAS G12D, KRAS G12V, or pan-KRAS inhibitors have entered clinical trials.

[0006] Currently, there are no specific targeted drugs for KRAS G12D, indicating a significant clinical need. KRAS G12D inhibitors, with higher selectivity, better activity, and better safety profiles, have the potential to treat a variety of cancers; pan-KRAS inhibitors are suitable for a wider range of patients and may have broader indications, both possessing promising market prospects. Summary of the Invention

[0007] The object of the present invention is to provide a compound of general formula (I) or a pharmaceutically acceptable salt thereof, the structure of which is shown below: M1 is selected from C, CH, or N; M2 is selected from C, CH, or N; L1 is selected from bond, O, S or NH; L is selected from bond, C1-C6 alkylene, C 3-8 Cycloalkylene, 3-8 membered heterocyclic alkylene, C1-C6 alkylene-C 3-8 Cycloalkylene or C1-C6 alkylene-3-8-membered heterocyclic alkylene, wherein the C1-C6 alkylene, C 3-8 Cycloalkylene groups and 3-8 membered heterocyclic groups may be replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, or C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Alternatively, two substituents on the same carbon atom in a C1-C6 alkylene group can be linked to form a C1-C6 alkylene group. 3-8cycloalkyl or 3-8 membered heterocyclic groups, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Ring A is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups; R is selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 aryl or 5-14 heteroaryl groups, wherein the above substituents may optionally be further replaced by 1, 2, 3, 4, 5 or 6 R groups. c replace; R1 is selected from C 6-10 Aryl or 5-10 heteroaryl, wherein the C 6-10 The aryl or 5-10 heteroaryl group can optionally be further divided by 1, 2, 3, 4, 5 or 6 R groups. e replace; R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R b1 Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, -(CR cc R dd ) n1 -C 3-12 cycloalkyl, -(CR cc R dd ) n1 -3-12-membered heterocyclic group, -(CR cc R dd ) n1 -C 6-14 Aryl, -(CR cc Rdd ) n1 -5-14 heteroaryl groups, -(CR cc R dd ) n1 -OR aa 、-(CR cc R dd ) n1 -SR aa 、-(CR cc R dd ) n1 -NR aa R bb 、-(CR cc R dd ) n1 -C(O)R aa 、-(CR cc R dd ) n1 -C(O)NR aa R bb 、-(CR cc R dd ) n1 -C(O)OR aa 、-(CR cc R dd ) n1 -OC(O)R aa 、-(CR cc R dd ) n1 -NR aa C(O)R bb 、-(CR cc R dd ) n1 -P(O)R aa R bb 、-(CR cc R dd ) n1 -S(O) m1 R aa 、-(CR cc R dd ) n1 -NR aa S(O) m1 R bb or -(CR) cc R dd ) n1 -S(O) m1 NR aa R bb The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R b2 Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, -(CR cc R dd ) n1 -C 3-12 cycloalkyl, -(CR cc R dd ) n1 -3-12-membered heterocyclic group, -(CR cc R dd ) n1 -C 6-14 Aryl, -(CR cc R dd ) n1 -5-14 heteroaryl groups, -(CR cc Rdd ) n1 -OR aa 、-(CR cc R dd ) n1 -SR aa 、-(CR cc R dd ) n1 -NR aa R bb 、-(CR cc R dd ) n1 -C(O)R aa 、-(CR cc R dd ) n1 -C(O)NR aa R bb 、-(CR cc R dd ) n1 -C(O)OR aa 、-(CR cc R dd ) n1 -OC(O)R aa 、-(CR cc R dd ) n1 -NR aa C(O)R bb 、-(CR cc R dd ) n1 -P(O)R aa R bb 、-(CR cc R dd ) n1 -S(O) m1 R aa 、-(CR cc R dd ) n1 -NR aa S(O) m1 R bb or -(CR) cc R dd ) n1 -S(O) m1 NR aa R bb The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, R b1 With R b2 The links form a 3-12 member heterocyclic group, which can optionally be further linked by 1, 2, 3, 4, 5 or 6 R groups. b Replacement; preferably forming a 3-8 member monocyclic heterocyclic group, a 7-12 member fused heterocyclic group, a 7-11 member spirocyclic heterocyclic group, or a 7-12 member bridged heterocyclic group, optionally further replaced by 1, 2, 3, 4, 5, or 6 R groups. b replace; R b Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, -(CH2) n1 -C 3-12 Cycloalkyl, -(CH2) n1 -3-12-membered heterocyclic group, -(CH2) n1 -C 6-14 Aryl, -(CH2) n1-5-14 heteroaryl groups, -(CH2) n1 -OR aa -(CH2) n1 -NR aa R bb -(CH2) n1 -C(O)R aa -(CH2) n1 -C(O)NR aa R bb -(CH2) n1 -NR aa C(O)R bb -(CH2) n1 -S(O) m1 R aa -(CH2) n1 -NR aa S(O) m1 R bb -(CH2) n1 -S(O) m1 NR aa R bb =CR aa R bb The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10One or more substitutions of aryl and 5-10 heteroaryl groups; Or, any two R b Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic groups, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions in aryl or 5-10 heteroaryl groups; R c Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl, 5-14 heteroaryl, =CR 1a R 1b =NOR 1a or -(CR) 1a R 1b ) n4 ORf, the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, any two R c Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic groups, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions in aryl or 5-10 heteroaryl groups; R e Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl, 5-14 heteroaryl, -OR 5a -NR 5a R 5b =CR 5a R 5b =N-OR 5b -NR 5a C(O)R 5b -P(O)R 5a R 5b -C(O)R 5a -C(O)NR 5a R 5b -S(O) m2 R 5a -S(O) m2 NR 5a R 5b or -S(O) m2 NR 5a R 5b The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl and 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, any two Re Link formation C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl, wherein the C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-10 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R f Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-15 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-15 Deuterated alkyl, C 1-15 Haloalkyl, C 1-15 Alkoxy, C 1-15 Alkylthio, C 1-15 Deuterated alkoxy, C 1-15 Halogenated alkoxy groups, C 1-15 Hydroxyalkyl, C 1-15 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl, 5-14 heteroaryl, -(CR 2a R 2b ) n5 R 2c 、-(CR 2a R 2b ) n5 OR 2c 、-(CR 2a R 2b ) n5 SR 2c 、-(CR 2a R 2b ) n5 NR 2c R 2d 、-(CR 2a R 2b )n5 P(O)R 2c R 2d 、-(CR 2a R 2b ) n5 C(O)R 2c 、-(CR 2a R 2b ) n5 C(O)NR 2c R 2d 、-(CR 2a R 2b ) n5 NR 2c C(O)R 2d 、-(CR 2a R 2b ) n5 S(O)R 2c 、-(CR 2a R 2b ) n5 S(O)2R 2c 、-(CR 2a R 2b ) n5 S(O)2NR 2c R 2d 、-(CR 2a R 2b ) n5 NR 2c S(O)2R 2d -(CH2CH2O) n5 R 2c Or -CH[CH2O(CH2CH2O) n5 R 2c ]2, the amino group, C 1-15 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-15 Deuterated alkyl, C 1-15 Haloalkyl, C 1-15 Alkoxy, C 1-15 Alkylthio, C 1-15 Deuterated alkoxy, C 1-15 Halogenated alkoxy groups, C 1-15 Hydroxyalkyl, C 1-15 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 1a and R 1b Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, oxo, thio, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, R 1a and R 1b Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic rings, wherein the C 3-8 The cycloalkyl group and 3-8 membered heterocycles may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 2a and R 2b Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, oxo, thio, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, R 2a and R 2b Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic rings, wherein the C 3-8 The cycloalkyl group and 3-8 membered heterocycles may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 2c and R 2d Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, oxo, thio, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-10 heteroaryl, -(CH2) n6 OR 2e and -(CH2) n6 C(O)R 2e One or more substitutions in; Or, R 2c and R 2d Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic rings, wherein the C 3-8 The cycloalkyl group and 3-8 membered heterocycles may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 2e Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 5a and R 5b Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, R 5a and R 5b The linkage forms a 3-8 membered heterocyclic group or a 5-10 membered heteroaryl group, wherein the 3-8 membered heterocyclic group and the 5-10 membered heteroaryl group may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R aa Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10One or more substitutions of aryl and 5-10 heteroaryl groups; R bb Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, R aa and R bb Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic groups, wherein the C 3-8Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are selected from aryl, 5-10 heteroaryl, =CH2, =CHF or =CF2; R cc Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R dd Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10One or more substitutions of aryl and 5-10 heteroaryl groups; a is selected from 0, 1, 2, 3 or 4; n1 is selected from 0, 1, 2, 3 or 4; n4 is selected from 0, 1, 2, 3 or 4; n5 is selected from 0, 1, 2, 3 or 4; n6 is selected from 0, 1, 2, 3 or 4; m1 is selected from 0, 1 or 2; m2 is selected from 0, 1 or 2; and m3 is selected from 0, 1 or 2.

[0008] In some embodiments of the present invention, L is selected from... , or ; R 3a R 3b R 3c and R 3d Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R d Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; d is selected from 0, 1, 2, 3 or 4.

[0009] In some embodiments of the invention, the compound or a pharmaceutically acceptable salt thereof is characterized in that it further represents, as shown in general formula (A) or (B): M1 is selected from C, CH, or N; M2 is selected from C, CH, or N; M3 is selected from CR. 4a R 4b or N-OR 4c ; M6 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, -(CH2) n1 -C 3-12 Cycloalkyl, -(CH2) n1 -3-12-membered heterocyclic group, -(CH2) n1 -C 6-14 Aryl, -(CH2) n1 -5-14 membered heteroaryl, or ; L1 is selected from O, S, or NH; O is preferred. Ring A is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups; Ring C is selected from C 3-12 Cycloalkyl or 3-12 membered heterocyclic groups; Ring D is selected from C 3-8 Cycloalkyl or 3-8 membered heterocyclic groups; preferably C 3-6 cycloalkyl; more preferably cyclopropyl; R1 is selected from C 6-10 Aryl or 5-10 heteroaryl, wherein the C 6-10 The aryl or 5-10 heteroaryl group can optionally be further divided by 1, 2, 3, 4, 5 or 6 R groups. e replace; R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, and C. 1-6 Alkyl, C 2-6alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 3a R 3b R 3c and R 3d Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 4a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, -(CR cc R dd ) n2 -C 3-12 cycloalkyl, -(CRcc R dd ) n2 -3-12-membered heterocyclic group, -(CR cc R dd ) n2 -C 6-14 Aryl, -(CR cc R dd ) n2 -5-14 heteroaryl groups, -(CR cc R dd ) n2 -OR ee 、-(CR cc R dd ) n2 -NR ee R ff 、-(CR cc R dd ) n2 -C(O)R ee 、-(CR cc R dd ) n2 -C(O)NR ee R ff 、-(CR cc R dd ) n2 -NR ee C(O)R ff 、-(CR cc R dd ) n2 -S(O) m2 R ee 、-(CR cc R dd ) n2 -NR ee S(O) m2 R ff or -(CR) cc R dd ) n2 -S(O) m2 NR ee R ff The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are selected from aryl and 5-10 heteroaryl groups; preferably hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 4b Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, -(CR cc R dd ) n2 -C 3-12 cycloalkyl, -(CR cc R dd ) n2 -3-12-membered heterocyclic group, -(CR cc R dd ) n2 -C 6-14 Aryl, -(CR cc R dd ) n2 -5-14 heteroaryl groups, -(CR cc R dd ) n2 -OR ee 、-(CR cc R dd ) n2 -NR ee R ff 、-(CR cc R dd ) n2 -C(O)R ee 、-(CR cc R dd ) n2 -C(O)NR ee R ff 、-(CR cc R dd ) n2 -NR eeC(O)R ff 、-(CR cc R dd ) n2 -S(O) m2 R ee 、-(CR cc R dd ) n2 -NR ee S(O) m2 R ff or -(CR) cc R dd ) n2 -S(O) m2 NR ee R ff The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are selected from aryl and 5-10 heteroaryl groups; preferably hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, R 4a and R 4b Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic groups, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions in aryl or 5-10 heteroaryl groups; R 4c Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, -(CR cc R dd ) n2 -C 3-12 cycloalkyl, -(CR cc R dd ) n2 -3-12-membered heterocyclic group, -(CR cc R dd ) n2 -C 6-14 Aryl, -(CR cc R dd ) n2 -5-14 heteroaryl groups, -(CR cc R dd ) n2 -OR ee 、-(CR cc R dd ) n2 -NR ee R ff 、-(CR cc R dd ) n2 -C(O)R ee 、-(CR cc R dd ) n2 -C(O)NR ee R ff 、-(CR cc R dd ) n2 -NR ee C(O)R ff 、-(CR cc R dd ) n2 -S(O) m3 R ee 、-(CR cc Rdd ) n2 -NR ee S(O) m3 R ff or -(CR) cc R dd ) n2 -S(O) m3 NR ee R ff The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are selected from aryl and 5-10 heteroaryl groups; preferably hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R b1 Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, -(CR cc R dd ) n1 -C 3-12 cycloalkyl, -(CR cc R dd ) n1 -3-12-membered heterocyclic group, -(CR cc R dd ) n1 -C 6-14 Aryl, -(CR cc R dd ) n1 -5-14 heteroaryl groups, -(CR cc R dd ) n1 -OR aa 、-(CR cc R dd ) n1 -SRaa 、-(CR cc R dd ) n1 -NR aa R bb 、-(CR cc R dd ) n1 -C(O)R aa 、-(CR cc R dd ) n1 -C(O)NR aa R bb 、-(CR cc R dd ) n1 -C(O)OR aa 、-(CR cc R dd ) n1 -OC(O)R aa 、-(CR cc R dd ) n1 -NR aa C(O)R bb 、-(CR cc R dd ) n1 -P(O)R aa R bb 、-(CR cc R dd ) n1 -S(O) m1 R aa 、-(CR cc R dd ) n1 -NR aa S(O) m1 R bb or -(CR) cc R dd ) n1 -S(O) m1 NR aa R bb The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are selected from aryl and 5-10 heteroaryl groups; preferably from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, -(CH2) n1 -C 3-12 Cycloalkyl, -(CH2) n1 -3-12-membered heterocyclic group, -(CH2) n1 -C 6-14 Aryl, -(CH2) n1 -5-14 heteroaryl groups, -(CH2) n1 -OR aa -(CH2) n1 -NR aa R bb -(CH2) n1 -C(O)R aa -(CH2) n1 -C(O)NR aa R bb -(CH2) n1 -NR aa C(O)R bb -(CH2) n1 -S(O) m1 R aa -(CH2) n1-NR aa S(O) m1 R bb Or -(CH2) n1 -S(O) m1 NR aa R bb The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R b2 Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, -(CR cc R dd ) n1 -C 3-12 cycloalkyl, -(CR cc Rdd ) n1 -3- to 12 - membered heterocyclic group, -(CR cc R dd ) n1 -C 6-14 aryl, -(CR cc R dd ) n1 -5- to 14 - membered heteroaryl, -(CR cc R dd ) n1 -OR aa 、-(CR cc R dd ) n1 -SR aa 、-(CR cc R dd ) n1 -NR aa R bb 、-(CR cc R dd ) n1 -C(O)R aa 、-(CR cc R dd ) n1 -C(O)NR aa R bb 、-(CR cc R dd ) n1 -C(O)OR aa 、-(CR cc R dd ) n1 -OC(O)R aa 、-(CR cc R dd ) n1 -NR aa C(O)R bb 、-(CR cc R dd ) n1 -P(O)R aa R bb 、-(CR cc R dd ) n1 -S(O) m1 R aa 、-(CR cc R dd ) n1 -NR aa S(O) m1 R bb or -(CR cc R dd )n1 -S(O) m1 NR aa R bb The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are selected from aryl and 5-10 heteroaryl groups; preferably from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, -(CH2) n1 -C 3-12 Cycloalkyl, -(CH2) n1 -3-12-membered heterocyclic group, -(CH2) n1 -C 6-14 Aryl, -(CH2) n1 -5-14 heteroaryl groups, -(CH2) n1 -ORaa -(CH2) n1 -NR aa R bb -(CH2) n1 -C(O)R aa -(CH2) n1 -C(O)NR aa R bb -(CH2) n1 -NR aa C(O)R bb -(CH2) n1 -S(O) m1 R aa -(CH2) n1 -NR aa S(O) m1 R bb Or -(CH2) n1 -S(O) m1 NR aa R bb The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, R b1 With R b2The links form a 3-12 member heterocyclic group, which can optionally be further linked by 1, 2, 3, 4, 5 or 6 R groups. b Replacement; preferably forming a 3-8 member monocyclic heterocyclic group, a 7-12 member fused heterocyclic group, a 7-11 member spirocyclic heterocyclic group, or a 7-12 member bridged heterocyclic group, optionally further replaced by 1, 2, 3, 4, 5, or 6 R groups. b replace; R b Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, -(CH2) n1 -C 3-12 Cycloalkyl, -(CH2) n1 -3-12-membered heterocyclic group, -(CH2) n1 -C 6-14 Aryl, -(CH2) n1 -5-14 heteroaryl groups, -(CH2) n1 -OR aa -(CH2) n1 -NR aa R bb -(CH2) n1 -C(O)R aa -(CH2) n1 -C(O)NR aa R bb -(CH2) n1 -NR aa C(O)R bb -(CH2) n1 -S(O) m1 R aa -(CH2) n1 -NR aa S(O) m1 R bb Or -(CH2) n1 -S(O) m1 NR aa R bb The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, any two R b Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic groups, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions in aryl or 5-10 heteroaryl groups; R c Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl, 5-14 quinone heteroaryl or -(CR 1a R 1b ) n4 ORf, the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are selected from aryl and 5-10 heteroaryl groups; preferably from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, any two R c Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic groups, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions in aryl or 5-10 heteroaryl groups; R d Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R e Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl, 5-14 heteroaryl, -OR 5a -NR 5a R 5b =CR 5a R 5b =N-OR 5b -NR 5a C(O)R 5b -P(O)R 5a R 5b -C(O)R 5a -C(O)NR 5a R 5b -S(O) m2 R 5a -S(O) m2 NR 5a R 5b or -S(O) m2 NR 5a R 5b The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl and 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are selected from aryl and 5-10 heteroaryl groups; preferably hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl, 5-14 heteroaryl, -OR 5a -NR 5a R 5b -NR 5a C(O)R 5b -P(O)R 5a R 5b -C(O)R 5a -C(O)NR 5a R 5b -S(O) m2 R 5a -S(O) m2 NR 5a R 5b or -S(O) m2 NR 5a R 5b The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl and 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, any two R e Link formation C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl, wherein the C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-10 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R f Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-15 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-15 Deuterated alkyl, C 1-15 Haloalkyl, C 1-15 Alkoxy, C 1-15 Alkylthio, C 1-15 Deuterated alkoxy, C 1-15 Halogenated alkoxy groups, C 1-15 Hydroxyalkyl, C 1-15 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14Aryl, 5-14 heteroaryl, -(CR 2a R 2b ) n5 R 2c 、-(CR 2a R 2b ) n5 OR 2c 、-(CR 2a R 2b ) n5 SR 2c 、-(CR 2a R 2b ) n5 NR 2c R 2d 、-(CR 2a R 2b ) n5 P(O)R 2c R 2d 、-(CR 2a R 2b ) n5 C(O)R 2c 、-(CR 2a R 2b ) n5 C(O)NR 2c R 2d 、-(CR 2a R 2b ) n5 NR 2c C(O)R 2d 、-(CR 2a R 2b ) n5 S(O)R 2c 、-(CR 2a R 2b ) n5 S(O)2R 2c 、-(CR 2a R 2b ) n5 S(O)2NR 2c R 2d 、-(CR 2a R 2b ) n5 NR 2c S(O)2R 2d -(CH2CH2O) n5 R 2c Or -CH[CH2O(CH2CH2O) n5 R 2c ]2, the amino group, C 1-15 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C1-15 Deuterated alkyl, C 1-15 Haloalkyl, C 1-15 Alkoxy, C 1-15 Alkylthio, C 1-15 Deuterated alkoxy, C 1-15 Halogenated alkoxy groups, C 1-15 Hydroxyalkyl, C 1-15 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 1a and R 1b Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, oxo, thio, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, R 1a and R 1b Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic rings, wherein the C 3-8 The cycloalkyl group and 3-8 membered heterocycles may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 2a and R 2b Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, oxo, thio, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, R 2a and R 2b Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic rings, wherein the C 3-8 The cycloalkyl group and 3-8 membered heterocycles may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 2c and R 2d Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, oxo, thio, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-10 heteroaryl, -(CH2) n6 OR 2e and -(CH2) n6 C(O)R 2e One or more substitutions in; Or, R2c and R 2d Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic rings, wherein the C 3-8 The cycloalkyl group and 3-8 membered heterocycles may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 2e Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 5a and R 5b Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, R 5a and R 5b The linkage forms a 3-8 membered heterocyclic group or a 5-10 membered heteroaryl group, wherein the 3-8 membered heterocyclic group and the 5-10 membered heteroaryl group may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R aa Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R bb Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, R aa and R bb Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic groups, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions in aryl or 5-10 heteroaryl groups; R cc Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R dd Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R ee Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R ff Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, R ee and R ff The linker forms a 3-12 membered heterocyclic group, which may optionally be further coupled with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, or C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are selected from aryl, 5-10 heteroaryl, =CH2, =CHF or =CF2; a is selected from 0, 1, 2, 3, or 4; c is selected from 0, 1, 2, 3, or 4; d is selected from 0, 1, 2, 3, or 4; n1 is selected from 0, 1, 2, 3, or 4; n2 is selected from 0, 1, 2, 3, or 4; n4 is selected from 0, 1, 2, 3, or 4; n5 is selected from 0, 1, 2, 3, or 4; n6 is selected from 0, 1, 2, 3, or 4; m2 is selected from 0, 1, or 2; and m3 is selected from 0, 1, or 2.

[0010] In some embodiments of the present invention, R b1 Selected from , 、-(CR cc R dd ) n1 -OR aa 、-(CR cc R dd ) n1 -SR aa 、-(CR cc R dd ) n1 -NR aa R bb 、-(CR cc R dd ) n1 -C(O)R aa 、-(CR cc R dd ) n1 -C(O)NR aa R bb 、-(CR cc R dd ) n1 -C(O)ORaa 、-(CR cc R dd ) n1 -NR aa C(O)R bb 、-(CR cc R dd ) n1 -P(O)R aa R bb 、-(CR cc R dd ) n1 -S(O) m1 R aa 、-(CR cc R dd ) n1 -NR aa S(O) m1 R bb or -(CR) cc R dd ) n1 -S(O) m1 NR aa R bb The C mentioned 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; preferably from 、-(CR cc R dd ) n1 -OR aa 、-(CR cc R dd ) n1 -SR aa 、-(CR cc R dd ) n1 -NR aa R bb 、-(CRcc R dd ) n1 -C(O)R aa 、-(CR cc R dd ) n1 -C(O)NR aa R bb 、-(CR cc R dd ) n1 -C(O)OR aa 、-(CR cc R dd ) n1 -NR aa C(O)R bb 、-(CR cc R dd ) n1 -P(O)R aa R bb 、-(CR cc R dd ) n1 -S(O) m1 R aa 、-(CR cc R dd ) n1 -NR aa S(O) m1 R bb or -(CR) cc R dd ) n1 -S(O) m1 NR aa R bb The C mentioned 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Substitution of aryl and one or more of 5-10 heteroaryl groups; preferably ; Rb2 Selected from hydrogen, C 1-6 Alkyl, C 1-6 Deuterated alkyl or C 1-6 Halogenated alkyl groups, optionally further reacted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; preferably from hydrogen, C 1-6 Alkyl, C 1-6 Deuterated alkyl or C 1-6 Halogenated alkyl groups; Ring B is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups; b is selected from 0, 1, 2, 3, or 4; R b As defined in any of the above implementation schemes.

[0011] In some embodiments of the present invention, M1 is selected from C or N; preferably C.

[0012] In some embodiments of the invention, M2 is selected from C or N; preferably C.

[0013] In some embodiments of the present invention, ring A is selected from C. 3-8 Cycloalkyl, 3-8 membered heterocyclic or 5-6 membered heteroaryl; The following groups are preferred: , , , , , , , , , , , or .

[0014] In certain embodiments of the invention, the compound represented by general formula (I) or a pharmaceutically acceptable salt thereof is further represented as shown in general formulas (A-1), (A-2), (B-1), or (B-2): L2 is selected from the key or C. 1-4 Alkylene, the C 1-4 Alkyl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, or C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; L3 is selected from bond, -O-, -C(O)-, -S(O)2-, -NR 6a -, -C(O)O-, -OC(O)-, -C(O)NR 6a -、-NR 6a C(O)-、-S(O)2NR 6a -or-NR 6a S(O)2-; L4 is selected from the bond, C(O) or C 1-4 Alkylene, the C 1-4 Alkyl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, or C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10One or more substitutions of aryl and 5-10 heteroaryl groups; R g Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 6a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; c-1 is selected from 0, 1, 2 or 3; f is selected from 0, 1 or 2.

[0015] In some embodiments of the present invention, R 4a Selected from hydrogen, deuterium, halogen, cyano, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, -(CR cc Rdd ) n2 -C 3-8 cycloalkyl, -(CR cc R dd ) n2 -3-8 membered heterocyclic group, -(CR cc R dd ) n2 -OR ee 、-(CR cc R dd ) n2 -NR ee R ff 、-(CR cc R dd ) n2 -C(O)R ee 、-(CR cc R dd ) n2 -C(O)NR ee R ff 、-(CR cc R dd ) n2 -NR ee C(O)R ff 、-(CR cc R dd ) n2 -S(O) m2 R ee 、-(CR cc R dd ) n2 -NR ee S(O) m2 R ff or -(CR) cc R dd ) n2 -S(O) m2 NR ee R ff The C mentioned 1-3 Alkyl C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; preferably hydrogen, deuterium, halogen, cyano, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 3-8 cycloalkyl or 3-8 membered heterocyclic groups, wherein the C 1-3 Alkyl C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are made of aryl and 5-10 heteroaryl groups; more preferably hydrogen, deuterium, fluorine, chlorine, bromine, methyl, ethyl, deuterated methyl, deuterated ethyl, halomethyl, haloethyl or cyclopropyl. R 4b Selected from hydrogen, deuterium, halogen, cyano, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 3-8 cycloalkyl or 3-8 membered heterocyclic groups, wherein the C 1-3 Alkyl C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are made of aryl and 5-10 heteroaryl groups; preferably hydrogen, deuterium, fluorine, chlorine, bromine, methyl, ethyl, deuterated methyl, deuterated ethyl, halomethyl, haloethyl or cyclopropyl.

[0016] In some embodiments of the present invention, R 4c Selected from hydrogen, deuterium, halogen, cyano, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, -(CR cc R dd ) n2 -C 3-8 cycloalkyl, -(CR cc R dd ) n2 -3-8 membered heterocyclic group, -(CR cc R dd ) n2 -OR ee 、-(CR ccR dd ) n2 -NR ee R ff 、-(CR cc R dd ) n2 -C(O)R ee 、-(CR cc R dd ) n2 -C(O)NR ee R ff 、-(CR cc R dd ) n2 -NR ee C(O)R ff 、-(CR cc R dd ) n2 -S(O) m2 R ee 、-(CR cc R dd ) n2 -NR ee S(O) m2 R ff or -(CR) cc R dd ) n2 -S(O) m2 NR ee R ff The C mentioned 1-3 Alkyl C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10One or more substitutions of aryl and 5-10 heteroaryl groups; preferably C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 3-8 cycloalkyl or 3-8 membered heterocyclic groups, wherein the C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more of aryl and 5-10 heteroaryl groups are substituted; more preferably methyl, ethyl, deuterated methyl, deuterated ethyl, halomethyl, haloethyl, cyclopropyl or cyclopropylmethyl.

[0017] In some embodiments of the present invention, ring C is selected from 3-8 member monocyclic heterocyclic groups, 7-10 member fused heterocyclic groups, 7-11 member spiroheterocyclic groups, or 7-10 member bridged heterocyclic groups; The following groups are preferred: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or ; More preferably, the following groups are preferred: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or ; Further preferred groups include: , , , , , , , , , , , , , , , , , , , , , , , , , , , or .

[0018] In some embodiments of the present invention, R d Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl or C 1-3 Alkylamino, the amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl and C 1-3 Alkylamino groups can optionally be further modified by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, or C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10One or more substitutions are made of aryl and 5-10 heteroaryl groups; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, nitro, hydroxyl, cyano, methyl, ethyl, deuterated methyl, deuterated ethyl, halomethyl or haloethyl.

[0019] In some embodiments of the present invention, R 3a R 3b R 3c and R 3d Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy or C 1-3 Hydroxyalkyl; preferably R 3a Selected from hydrogen or deuterium; R 3b Selected from hydrogen or deuterium; R 3c Selected from hydrogen or deuterium; R 3d Selected from hydrogen or deuterium.

[0020] In some embodiments of the present invention, R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl or C 1-3 Alkylamino; preferably, R2 is selected from hydrogen, deuterium, fluorine, chlorine or bromine; more preferably, R2 is selected from fluorine.

[0021] In some embodiments of the present invention, ring B is selected from C. 3-8 cycloalkyl, C 7-12 Fused cycloalkyl, 3-8 membered monocyclic heterocyclic group, 7-12 membered fused heterocyclic group, 7-11 membered spirocyclic group, 7-12 membered bridged heterocyclic group or 5-10 membered heteroaryl group; Preferably, it is derived from 3-8 member monocyclic heterocyclic groups, 7-12 member fused heterocyclic groups, 7-11 member spiroheterocyclic groups, or 7-12 member bridged heterocyclic groups; More preferably, the following groups are preferred: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or ; Further preferred groups include: , , , , , , , , , , , , , , , , , , , , , , , , , , , or ; Further preferred groups include: , , , , , , , , , , , , , , or .

[0022] In some embodiments of the present invention, R b Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, -(CH2) n1 -C 3-8 Cycloalkyl, -(CH2) n1 -3-8 membered heterocyclic group, -(CH2) n1 -C 6-10 Aryl, -(CH2) n1 -5-10 heteroaryl groups, -(CH2) n1 -OR aa -(CH2) n1 -NR aa R bb -(CH2) n1 -C(O)R aa -(CH2) n1 -C(O)NR aa R bb -(CH2) n1 - NR aa C(O)R bb -(CH2) n1 -S(O) m1 R aa -(CH2) n1 -NR aa S(O) m1 R bb -(CH2) n1 -S(O)m1 NR aa R bb or =CR aa R bb The amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl and C 1-3 Alkylamino groups can optionally be further modified by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, or C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are selected from aryl and 5-10 heteroaryl groups; preferably from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, -(CH2) n1 -C 3-8 Cycloalkyl, -(CH2) n1 -3-8 membered heterocyclic group, -(CH2) n1 -C 6-10 Aryl, -(CH2) n1 -5-10 heteroaryl groups, -(CH2) n1 -OR aa -(CH2) n1 -NR aa Rbb -(CH2) n1 -C(O)R aa -(CH2) n1 -C(O)NR aa R bb -(CH2) n1 - NR aa C(O)R bb -(CH2) n1 -S(O) m1 R aa -(CH2) n1 -NR aa S(O) m1 R bb Or -(CH2) n1 -S(O) m1 NR aa R bb The amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl and C 1-3 Alkylamino groups can optionally be further modified by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, or C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups.

[0023] In some embodiments of the present invention, R a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl or C 1-3 Alkylamino, the amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl and C 1-3 Alkylamino groups can optionally be further modified by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, or C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Preferred radicals include hydrogen, deuterium, fluorine, chlorine, bromine, amino, nitro, hydroxyl, cyano, methyl, ethyl, deuterated methyl, deuterated ethyl, halomethyl, or haloethyl.

[0024] In some embodiments of the present invention, R1 is selected from... , , or Preferred , or ; M9 is selected from CR 6-5 Or N; M4 is selected from CR 7-1 Or N; M5 is selected from CR 8-2 Or N; Preferably, R1 is selected from , , , , , , , , , , , , , , , , , , , , , or ; Preferably, R1 is selected from , , , , , , , , , , , , , , , , or ; Preferably, R1 is selected from , , , , , , , , , , , , , or ; Preferably, R1 is selected from , , , , , , , , , or ; R 5-1 R 5-2 R 5-3 R 5-4R 5-5 R 5-6 and R 5-7 Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-10 heteroaryl, -OR 5a -NR 5a R 5b -NR 5a C(O)R 5b -P(O)R 5a R 5b -C(O)R 5a -C(O)NR 5a R 5b -S(O) m2 R 5a -S(O) m2 NR 5a R 5b or -S(O) m2 NR 5a R 5b The amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are selected from aryl and 5-10 heteroaryl groups; preferably hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl, wherein the amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 6-1 R 6-2 R 6-3 R 6-4 and R 6-5 Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-10 heteroaryl, -OR 5a -NR 5a R 5b -NR 5a C(O)R 5b -P(O)R 5a R 5b -C(O)R 5a -C(O)NR 5a R 5b -S(O) m2 R 5a -S(O) m2 NR 5a R 5b or -S(O) m2 NR 5a R 5b The amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10Aryl or 5-10 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are selected from aryl and 5-10 heteroaryl groups; preferably hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl, wherein the amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 7-1 R 7-2 R 7-3 R 7-4 and R 7-5 Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-10 heteroaryl, -OR 5a -NR 5a R 5b -NR 5a C(O)R 5b -P(O)R 5a R 5b -C(O)R 5a -C(O)NR 5a R 5b -S(O) m2 R 5a -S(O) m2 NR 5a R 5b or -S(O) m2 NR 5a R 5b The amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are selected from aryl and 5-10 heteroaryl groups; preferably hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl, wherein the amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10Aryl or 5-10 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 8-1 Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl, 5-14 heteroaryl, -OR 5a -NR 5a R 5b =CR 5a R 5b =N-OR 5b -NR 5a C(O)R 5b -P(O)R 5a R 5b -C(O)R 5a -C(O)NR 5a R 5b -S(O) m2 R 5a -S(O) m2 NR 5a R 5b or -S(O) m2 NR 5a R 5b The amino group, C1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl and 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are selected from aryl and 5-10 heteroaryl groups; preferably hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, any two R 8-1 Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic groups, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions in aryl or 5-10 heteroaryl groups; R 8-2 R 8-3 and R 8-4 Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-10 heteroaryl, -OR 5a -NR 5a R 5b -NR 5a C(O)R 5b -P(O)R 5a R 5b -C(O)R 5a -C(O)NR 5a R 5b -S(O) m2 R 5a -S(O) m2 NR 5a R 5b or -S(O) m2 NR 5a R 5b The amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are selected from aryl and 5-10 heteroaryl groups; preferably hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl, wherein the amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; n3 is selected from 0, 1, or 2; and u is selected from 0, 1, 2, 3, 4, 5, or 6.

[0025] In some embodiments of the invention, the compound or a pharmaceutically acceptable salt thereof is further represented as shown in general formulas (C-1), (C-2), (C-3), or (C-4): M is selected from -O-, -NR p -, -S(O)-, -S(O)2-, -S(O)(NR p )-、-S(O)2-NR p -、-S(O)R p =N- or -P(O)R p -; R p Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; b is selected from 0, 1, 2, 3, 4, 5, or 6; c is selected from 0, 1, 2, 3, 4, 5, or 6; n7 is selected from 0, 1, 2, 3, or 4; n8 is selected from 0, 1, 2, 3, or 4; L2, L3, R b As defined in any of the above implementation schemes.

[0026] In some embodiments of the invention, the compound or a pharmaceutically acceptable salt thereof is further represented as shown in general formula (A-2-1) or (B-2-1): .

[0027] In some embodiments of the invention, the compound or a pharmaceutically acceptable salt thereof is further represented as shown in general formula (A-1-1), (B-1-1), or (B-1-2): M7 is selected from C, CH, or N; preferably C or N; M8 is selected from C, CH or N; preferably C or N; Ring F is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl groups; R m Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl, wherein the amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R n Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl, wherein the amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; m is selected from 0, 1, 2, 3, 4 or 5; n is selected from 0, 1, 2, 3, 4 or 5; n8 is selected from 0, 1, 2 or 3; n9 is selected from 0, 1, 2 or 3; n10 is selected from 0, 1, 2 or 3.

[0028] In some embodiments of the present invention, R f Selected from C 1-15 Alkyl, C 1-15 Deuterated alkyl, C 1-15 Haloalkyl, C 1-15 Alkoxy, C 1-15 Alkylthio, C 1-15 Deuterated alkoxy, C 1-15 Halogenated alkoxy groups, C 1-15 Hydroxyalkyl, C 1-15 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl, 5-14 heteroaryl, -(CR 2a R 2b ) n5 R 2c 、-(CR 2a R 2b ) n5 OR 2c 、-(CR 2a R 2b ) n5 SR 2c 、-(CR 2a R 2b ) n5 NR2c R 2d 、-(CR 2a R 2b ) n5 P(O)R 2c R 2d 、-(CR 2a R 2b ) n5 C(O)R 2c 、-(CR 2a R 2b ) n5 C(O)NR 2c R 2d 、-(CR 2a R 2b ) n5 NR 2c C(O)R 2d 、-(CR 2a R 2b ) n5 S(O)R 2c 、-(CR 2a R 2b ) n5 S(O)2R 2c 、-(CR 2a R 2b ) n5 S(O)2NR 2c R 2d 、-(CR 2a R 2b ) n5 NR 2c S(O)2R 2d -(CH2CH2O) n5 R 2c Or -CH[CH2O(CH2CH2O) n5 R 2c ]2, the aforementioned C 1-15 Alkyl, C 1-15 Deuterated alkyl, C 1-15 Haloalkyl, C 1-15 Alkoxy, C 1-15 Alkylthio, C 1-15 Deuterated alkoxy, C 1-15 Halogenated alkoxy groups, C 1-15 Hydroxyalkyl, C 1-15 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 2a and R 2b Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl, wherein the amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-10 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, R 2a and R 2b Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic rings, wherein the C 3-8 The cycloalkyl group and 3-8 membered heterocycles may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 2c and R 2d Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-10 heteroaryl, -(CH2) n6 OR 2e and -(CH2) n6 C(O)R 2e One or more substitutions in; R 2e Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl, wherein the amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10Aryl and 5-10 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; n5 is selected from 0, 1, 2, or 3; n6 is selected from 0, 1, 2, or 3; Preferably, R f Selected from C 1-15 Alkyl groups, -CH2CH2OCH3, -(CH2CH2O)2CH3, -(CH2CH2O)2CH2F, -(CH2CH2O)2CH2CF3, -(CH2CH2O)3CH3 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or .

[0029] The present invention also provides a method for preparing a compound of general formula (A-1-1), its stereoisomers or pharmaceutically acceptable salts thereof, comprising the following step 1: The compound of general formula (A-1-2) reacts with the compound of general formula (A-1-3) under alkaline conditions to give the compound of general formula (A-1-1); Optionally, step 2 may be further included: The compound of general formula (A-1-4) reacts with the compound of general formula (A-1-5) under basic conditions to give the compound of general formula (A-1-2); R L1 Selected from halogens; preferably chlorine or bromine; R L2 Selected from borate group, borate group, chain borate ester group or cyclic borate ester group; R L3 Selected from halogens, hydroxyl groups, or -S(O). m2 -C 1-3 Alkyl group; preferably chlorine, bromine, -S(O)-CH3 or -S(O)2-CH3; m2 is selected from 0, 1, or 2; R a R2, R b2 a, R d, d, R c M3, c, ring B, R b b, n1, M9, R 6-1 ~R 6-5 n8 and n9 are as defined in any of the above implementation schemes.

[0030] In some embodiments of the present invention, R L2 Selected from substituted or unsubstituted or Preferred , or ; R L5 Selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, mercapto, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 2-4 alkenyl, C 2-4 Haloalkenyl, C 2-4 alkynyl or C 3-8 cycloalkyl; a is selected from 0, 1, 2, 3, 4, 5, or 6; In some embodiments of the invention, the coupling reaction is carried out in the presence of a palladium catalyst.

[0031] In some embodiments of the present invention, the palladium catalyst is selected from palladium on carbon, palladium acetate, palladium dichloride diphenylphosphine, tetratriphenylphosphine palladium, bis(triphenylphosphine)palladium dichloride, bis(bisphenylphosphine phenyl ether)palladium dichloride, [(bis(1-adamantyl)butylphosphino)-2-(2′-amino-1,1′-biphenyl)]palladium(II) methanesulfonate, methanesulfonate (dimethyl-n-butylphosphino)-2'-amino-1,1'-biphenyl-2-yl)palladium(II) dichloromethane adduct, or methanesulfonate [n-butylbis(1-adamantyl)phosphino](2-amino-1,1'-biphenyl-2-yl)palladium(II); In some embodiments of the present invention, the alkali is selected from sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium hydride, sodium n-propoxide, sodium tert-butoxide, potassium tert-butoxide, or lithium bis(trimethylsilyl)amide; preferably sodium hydride.

[0032] The present invention also provides a pharmaceutical composition comprising a therapeutically effective dose of the above-described compound or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients.

[0033] In some embodiments of the invention, the above-mentioned compound or its pharmaceutically acceptable salt constitutes 0.1% to 95% by weight in the composition, preferably 0.5% to 85%, more preferably 1% to 60%, further preferably 10% to 50%, even more preferably 15-40%, even more preferably 20-30%, and even more preferably 20-25% (based on the total weight of the pharmaceutical composition).

[0034] In some embodiments of the invention, the pharmaceutical composition is selected from tablets, capsules, liquid formulations, injections, suspensions, powders, granules, or lozenges, preferably also containing a filler, optionally a disintegrant, or further containing one or more of a flow aid or lubricant.

[0035] In some embodiments of the present invention, the pharmaceutical composition is an immediate-release formulation or a sustained-release formulation.

[0036] The present invention further relates to the use of the above-mentioned compounds or pharmaceutically acceptable salts thereof, or the pharmaceutical compositions thereof, in the preparation of KRAS inhibitor medicaments; preferably in the use of KRAS G12C, KRAS G12D, KRAS G12V, KRAS G12S or KRASG13D inhibitor medicaments.

[0037] The present invention further relates to the use of the above-mentioned compounds or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, in the preparation of medicaments for treating diseases or conditions of Noonan syndrome, panther syndrome, leukemia, neuroblastoma, melanoma, esophageal cancer, head and neck tumors, breast cancer, lung cancer, pancreatic cancer, and colorectal cancer; preferably in the preparation of medicaments for treating non-small cell lung cancer, pancreatic cancer, colon cancer, esophageal cancer, and head and neck tumors.

[0038] The present invention further relates to methods for preparing treatments of the above-mentioned compounds or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, for the treatment of diseases or conditions of Noonan syndrome, panther syndrome, leukemia, neuroblastoma, melanoma, esophageal cancer, head and neck tumors, breast cancer, lung cancer, pancreatic cancer, and colorectal cancer; preferably, methods for preparing treatments of non-small cell lung cancer, pancreatic cancer, colon cancer, esophageal cancer, and head and neck tumors.

[0039] The present invention also relates to a method for treating, preventing, and / or treating pre-prepared treatments for Noonan syndrome, panther syndrome, leukemia, neuroblastoma, melanoma, esophageal cancer, head and neck tumors, breast cancer, lung cancer, pancreatic cancer, and colorectal cancer, comprising administering to a patient a therapeutically effective dose of the aforementioned compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof; preferably in the preparation of a method for treating non-small cell lung cancer, pancreatic cancer, colon cancer, esophageal cancer, and head and neck tumors.

[0040] In some embodiments of the present invention, the above-mentioned disease or condition is a disease or condition mediated by a KRAS mutation; the KRAS mutation is selected from KRAS G12C, KRAS G12D, KRAS G12V, KRAS G12S or KRAS G13D mutations.

[0041] In some embodiments of the invention, the above-mentioned compounds or their pharmaceutically acceptable salts may be administered by any convenient method, such as oral, parenteral, oral, sublingual, nasal, rectal, intrathecal, or transdermal administration, and accordingly modified pharmaceutical compositions.

[0042] Detailed description of the invention Unless otherwise stated, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art, and in particular, the terms used in the specification and claims have the following meanings.

[0043] The term "alkyl" refers to a straight-chain or branched saturated aliphatic hydrocarbon group, which may optionally be substituted with one or more substituents. In certain embodiments, alkyl refers to a group having a carbon density of 1 to 20 (C). 1-20 ), 1 to 15 (C 1-15 ), 1 to 12 (C 1-12 ), 1 to 10 (C 1-10 ), 1 to 8 (C 1-8 ), 1 to 6 (C 1-6 ) or 1 to 3 (C 1-3 A straight-chain saturated hydrocarbon group with 3 to 20 carbon atoms, or a group with 3 to 20 carbon atoms. 3-20 ), 3 to 15 (C 3-15 ), 3 to 12 (C 3-12 ), 3 to 10 (C 3-10 ), 3 to 8 (C 3-8 ) or 3 to 6 (C 3-6 A branched saturated hydrocarbon group with 1 carbon atom. The straight-chain C group used here... 1-6 Alkyl and branched C 3-6 Alkyl groups are also called "lower alkyl groups". For example, C 1-6 Alkyl groups refer to linear saturated monovalent hydrocarbon groups having 1 to 6 carbon atoms or branched saturated monovalent hydrocarbon groups having 3 to 6 carbon atoms. In one embodiment, the C 1-6The alkyl group contains 1 to 6 carbon atoms (e.g., 1, 2, 3, 4, 5, 6). Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2, 3-Dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched isomers thereof. In one embodiment, the alkyl group is an optionally substituted alkyl group as described elsewhere herein.

[0044] The term "alkylene" refers to an alkyl group in which one hydrogen atom is further substituted, wherein "alkyl" is defined as described above. Non-limiting examples of "alkylene" include methylene (-CH2-), ethylene (-(CH2)2-), propylene (-(CH2)3-), or butylene (-(CH2)4-). In one embodiment, the alkylene is an optionally substituted alkyl group as described elsewhere herein.

[0045] The term "alkenyl" refers to a straight-chain or branched unsaturated aliphatic hydrocarbon group containing at least one carbon-carbon double bond, which can be located at any position within the alkenyl group, and the alkenyl group may optionally be substituted by one or more substituents. In a particular embodiment, the alkenyl group has a carbon content of 2 to 20 (C₂O₃). 2-20 ), 2 to 15 (C 2-15 ), 2 to 12 (C 2-12 ), 2 to 10 (C 2-10 ), 2 to 8 (C 2-8 ), 2 to 6 (C 2-6 ) or 2 to 4 (C 2-4 A straight-chain unsaturated hydrocarbon group with 3 to 20 carbon atoms, or having a carbon atom content of 3 to 20. 3-20 ), 3 to 15 (C3-15 ), 3 to 12 (C 3-12 ), 3 to 10 (C 3-10 ), 3 to 8 (C 3-8 ) or 3 to 6 (C 3-6 A branched unsaturated hydrocarbon group with 16 carbon atoms. Unless otherwise specified, the term "alkenyl" as used herein includes both straight-chain and branched alkenyl groups. For example, C 2-6 Alkenyl refers to a straight-chain unsaturated hydrocarbon group having 2 to 6 carbon atoms or a branched unsaturated hydrocarbon group having 3 to 6 carbon atoms. In one embodiment, the C 2-6 Alkenyl groups contain 2 to 6 (e.g., 2, 3, 4, 5, or 6) carbon atoms. Non-limiting examples of alkenyl groups include: , , , , or Those skilled in the art will understand that the term "alkenyl" may also include groups having "cis" and "trans" configurations, or alternatively, "E" and "Z" configurations. In one embodiment, the alkenyl is an optionally substituted alkenyl as described elsewhere herein.

[0046] The term "alkynyl" refers to a straight-chain or branched unsaturated aliphatic hydrocarbon group containing at least one carbon-carbon triple bond, which can be located at any position within the alkynyl group. The alkynyl group may optionally be substituted by one or more substituents. In a particular embodiment, the alkynyl group has a carbon content of 2 to 20 (C₂O₃). 2-20 ), 2 to 15 (C 2-15 ), 2 to 12 (C 2-12 ), 2 to 10 (C 2-10 ), 2 to 8 (C 2-8 ), 2 to 6 (C 2-6 ) or 2 to 4 (C 2-4 A straight-chain unsaturated hydrocarbon group with 3 to 20 carbon atoms, or having a carbon atom content of 3 to 20. 3-20 ), 3 to 15 (C 3-15 ), 3 to 12 (C 3-12 ), 3 to 10 (C 3-10 ), 3 to 8 (C 3-8 ) or 3 to 6 (C 3-6 A branched unsaturated hydrocarbon group with 12 carbon atoms. Unless otherwise specified, the term "alkynyl" as used herein includes both straight-chain and branched alkynyl groups. For example, C 2-6 Alkyne refers to a straight-chain unsaturated hydrocarbon group having 2 to 6 carbon atoms or a branched unsaturated hydrocarbon group having 3 to 6 carbon atoms. In one embodiment, the C 2-6The alkynyl group contains 2 to 6 (e.g., 2, 3, 4, 5, 6) carbon atoms. Non-limiting examples of the alkynyl group include: , , or In one embodiment, the alkynyl group is an optionally substituted alkynyl group as described elsewhere herein.

[0047] The term "cycloalkyl" refers to a monocyclic or polycyclic (two or more) cyclic group of a saturated or partially unsaturated aliphatic hydrocarbon, which may optionally be substituted with one or more substituents. In certain embodiments, the cycloalkyl ring comprises 3 to 20 (C 3-20 ), 3 to 12 (C 3-12 ), 3 to 8 (C 3-8 ) or 3 to 6 (C 3-6 ) carbon atoms; in one embodiment, the cycloalkyl ring comprises 6 to 14 (C 6-14 ) or 7 to 10 (C 7-10 It has 10 carbon atoms; it may contain one or more double bonds, but does not have a fully conjugated π-electron system. Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenedyl, cyclohexadienyl, cycloheptyl, cyclohepttrienyl, or cyclooctyl, etc.; polycyclic cycloalkyl groups include spirocyclic alkyl, fused cycloalkyl, and bridged cycloalkyl. In one embodiment, the cycloalkyl group is an optionally substituted cycloalkyl group or an optionally fused cycloalkyl group with a heterocyclic group, aryl group, or heteroaryl group, as described elsewhere herein, and non-limiting examples include indanyl, tetrahydronaphthyl, benzocycloheptyl, etc.

[0048] The term "spirocycloalkyl" refers to an aliphatic hydrocarbon polycyclic group that shares a single carbon atom (called a spiro atom) between its monocyclic rings. It may contain one or more double bonds, but none of the rings has a fully conjugated π-electron system. In certain embodiments, the spirocycloalkyl group comprises 5 to 20 carbon atoms. 5-20 ), 6 to 14 (C 6-14 ) or 7 to 10 (C 7-10 (e.g., 7, 8, 9, 10) carbon atoms. Spirocycloalkyl groups are classified as monospirocycloalkyl, bispirocycloalkyl, or polyspirocycloalkyl groups based on the number of shared spiro atoms between rings, with one embodiment being monospirocycloalkyl and bispirocycloalkyl. In one embodiment, it is a 4-membered / 4-membered, 3-membered / 5-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered, or 5-membered / 6-membered monospirocycloalkyl. In one embodiment, the spirocycloalkyl group is an optionally substituted spirocycloalkyl group described elsewhere herein. Non-limiting examples of spirocycloalkyl groups include: .

[0049] The term "fused-cycle alkyl" refers to a fully carbon polycyclic group in which each ring in a system shares an adjacent pair of carbon atoms with the other rings in the system, wherein one or more rings may contain one or more double bonds, but no ring has a fully conjugated π-electron system. In a particular embodiment, the fused-cycle alkyl comprises 5 to 20 (C 5-20 ), 6 to 14 (C 6-14 ) or 7 to 10 (C 7-10 (e.g., 7, 8, 9, 10) carbon atoms. Depending on the number of rings, they can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic fused-ring alkyl groups. In one embodiment, they are bicyclic or tricyclic, and in another embodiment, they are 3-membered / 5-membered, 4-membered / 5-membered, 5-membered / 5-membered, or 5-membered / 6-membered bicyclic alkyl groups. In one embodiment, the fused-ring alkyl group is an optionally substituted fused-ring alkyl group described elsewhere herein or an fused-ring alkyl group optionally fused with a heterocyclic group, aryl group, or heteroaryl group. Non-limiting examples of fused-ring alkyl groups include: , , , , , or .

[0050] The term "bridged cycloalkyl" refers to a fully carbon polycyclic group in which any two rings share two non-directly bonded carbon atoms. It may contain one or more double bonds, but none of the rings has a fully conjugated π-electron system. In certain embodiments, the bridged cycloalkyl group comprises 5 to 20 (C...) 5-20 ), 6 to 14 (C 6-14 ) or 7 to 10 (C 7-10 (e.g., 7, 8, 9, 10) carbon atoms. Depending on the number of rings, they can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic bridged alkyl groups, preferably bicyclic or tricyclic. In one embodiment, the bridged alkyl group is an optionally substituted bridged alkyl group described elsewhere herein. Non-limiting examples of bridged alkyl groups include: .

[0051] The term "heterocyclic group" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon group, wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen, boron, phosphorus, or sulfur, wherein the nitrogen, phosphorus, or sulfur atom may optionally be oxidized, the nitrogen atom may optionally be quaternized, the ring carbon atom may optionally be substituted with oxygen, excluding the -OO- or -OS- ring moiety, and the remaining ring atoms are carbon, which may contain one or more double bonds but does not have a fully conjugated π-electron system. In a particular embodiment, the heterocyclic group comprises 3 to 20, 3 to 12, 3 to 8, or 3 to 6 ring atoms, wherein 1 to 4 are heteroatoms; in one embodiment, the heterocyclic group comprises 3 to 6, 4 to 6, 3 to 8, 3 to 10, 6 to 10, or 7 to 11 ring atoms; in one embodiment, the heterocyclic group comprises 3 to 8 (e.g., 3, 4, 5, 6, 7, 8) ring atoms. Non-limiting examples of monocyclic heterocyclic groups include tetrahydropyrrole, azahexacyclic butyl, oxacyclobutyl, oxacyclohexyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrole, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, and pyranyl. Polycyclic heterocyclic groups include spiroheterocyclic, fused heterocyclic, and bridged heterocyclic groups. In one embodiment, the heterocyclic group is optionally substituted as described elsewhere herein, or is a heterocyclic group further cyclically linked to other cycloalkyl, heterocyclic, aryl, and heteroaryl groups by any two or more atoms on the ring.

[0052] The term "spiroheterocyclic group" refers to a polycyclic heterocyclic group in which one or more ring atoms share a single atom (called a spiro atom), wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen, boron, phosphorus, or sulfur, and the remaining ring atoms are carbon. It may contain one or more double bonds, but none of the rings has a fully conjugated π-electron system. In certain embodiments, the spiroheterocyclic group comprises 5 to 20 or 6 to 14 ring atoms; in one embodiment, it comprises 7 to 11 (e.g., 7, 8, 9, 10, 11) ring atoms; spiroheterocyclic groups are classified as monospirocyclic, bispirocyclic, or multispirocyclic groups according to the number of spiro atoms shared between the rings; monospirocyclic and bispirocyclic groups are preferred; in one embodiment, the spiroheterocyclic group is a 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered, or 5-membered / 6-membered monospirocyclic group; in one embodiment, the spiroheterocyclic group is an optionally substituted spiroheterocyclic group described elsewhere herein; non-limiting examples of spiroheterocyclic groups include: , , , , , , , , , , , , or .

[0053] The term "fused heterocyclic group" refers to a polycyclic heterocyclic group in which each ring in a system shares an adjacent pair of atoms with other rings in the system. One or more rings may contain one or more double bonds, but none of the rings has a fully conjugated π-electron system. One or more ring atoms are heteroatoms selected from nitrogen, oxygen, boron, phosphorus, or sulfur, and the remaining ring atoms are carbon. In a particular embodiment, the fused heterocyclic group comprises 5 to 20 or 6 to 14 ring atoms, and in one embodiment comprises 7 to 10 (e.g., 7, 8, 9, 10) ring atoms; it can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic fused heterocyclic groups depending on the number of constituent rings; bicyclic or tricyclic is preferred; in one embodiment, it is a 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused heterocyclic group; in one embodiment, the fused heterocyclic group is optionally substituted as described elsewhere herein, or a fused heterocyclic group that can be fused with cycloalkyl, heterocyclic, aryl, or heteroaryl groups; non-limiting examples of fused heterocyclic groups include: , , , , , , , , , , , , , , , , , , , , , or .

[0054] The term "bridged heterocyclic group" refers to a polycyclic heterocyclic group in which any two rings share two non-directly bonded atoms. It may contain one or more double bonds, but none of the rings has a fully conjugated π-electron system. One or more ring atoms are heteroatoms selected from nitrogen, oxygen, boron, phosphorus, or sulfur, and the remaining ring atoms are carbon. In certain embodiments, the bridged heterocyclic group comprises 5 to 20 or 6 to 14 ring atoms; in one embodiment, it comprises 7 to 10 (e.g., 7, 8, 9, 10) ring atoms; depending on the number of constituent rings, it can be classified as a bicyclic, tricyclic, tetracyclic, or polycyclic bridged heterocyclic group; preferably bicyclic, tricyclic, or tetracyclic; in one embodiment, it is bicyclic or tricyclic; in one embodiment, the bridged heterocyclic group is an optionally substituted bridged heterocyclic group described elsewhere herein; non-limiting examples of bridged heterocyclic groups include: , , , , , , , or .

[0055] The term "aryl" refers to an all-carbon monocyclic or fused polycyclic (i.e., a ring sharing adjacent carbon atom pairs) group containing at least one conjugated π-electron system, which may optionally be substituted by one or more substituents. In certain embodiments, the aryl group comprises 6 to 20, 6 to 14, or 6 to 10 ring atoms; in one embodiment, the aryl group may further refer to a bicyclic, tricyclic, or tetracyclic ring system, wherein at least one ring is an aromatic ring, and the other rings may be saturated, partially unsaturated carbon rings, or rings containing one or more heteroatoms independently selected from O, S, and N; in one embodiment, the aryl group is selected from benzo5-10-membered heteroaryl, benzo3-10-membered cycloalkyl, or benzo3-10-membered heterocyclic groups. In one embodiment, the aryl group is selected from benzo5-6-membered heteroaryl, benzo3-6-membered cycloalkyl, or benzo3-6-membered heterocyclic groups, wherein the heterocyclic group is a heterocyclic group containing 1 to 3 nitrogen, oxygen, or sulfur atoms. Non-limiting examples include phenyl, naphthyl, fluorenyl, chamomilecycloyl, anthraceneyl, phenanthryl, pyrene, biphenyl, terphenyl, dihydronaphthyl, indene, tetrahydronaphthyl (naphthyl), , , , , , , , , , , , , and .

[0056] The term "arylene" refers to a divalent aryl group formed by further substitution of one hydrogen atom of an aryl group, wherein the arylene group may be optionally substituted or unsubstituted, as defined above for aryl groups.

[0057] The term "heteroaryl" refers to an optionally substituted monocyclic, polycyclic group or ring system comprising at least one aromatic ring having one or more heteroatoms independently selected from O, S, and N. In certain embodiments, a heteroaryl comprises 5 to 20, 5 to 14, or 5 to 10 ring atoms, of which 1 to 4 are heteroatoms; in one embodiment, a heteroaryl comprises 5 or 6 ring atoms; in certain embodiments, a heteroaryl may further refer to a bicyclic, tricyclic, or tetracyclic ring, wherein at least one ring is an aromatic ring having one or more heteroatoms independently selected from O, S, and N, and the other rings may be saturated, partially unsaturated carbocyclic rings, or rings comprising one or more heteroatoms independently selected from O, S, and N. In one embodiment, the heteroaryl group is selected from heteroaryl-6-10 aryl, heteroaryl-3-10 cycloalkyl, or heteroaryl-3-10 heterocyclic group; in a further embodiment, the heteroaryl group is selected from 5- or 6-membered heteroaryl-6-10 aryl, 5- or 6-membered heteroaryl-3-6 cycloalkyl, or 5- or 6-membered heteroaryl-3-6 heterocyclic group, wherein the heterocyclic group is a heterocyclic group containing 1-3 nitrogen atoms, oxygen atoms, or sulfur atoms. Non-limiting examples include: furanyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrroloyl, thiadiazolyl, thiazolyl, thiophene, tetrazolyl, triazinyl, triazolyl, benzofuranyl, benzimidazolyl, benziisoxazolyl, benzopyranyl, benzothiadiazolyl, benzothiaphenyl, benzobenzenethio, benzothiaphenyl, benzotriazolyl, imidazopyridyl, imidazothiazolyl Indazinyl, indolyl, inzolyl, isobenzofuranyl, isobenzothiophenyl, isoindolyl, isoquinolinyl, naphridinyl, oxazolopyridyl, phthalazinyl, pteridinyl, purine, pyridopyridyl, pyrrolopyridyl, quinolinyl, quinoxolinyl, quinazolinyl, thiadiazopyrimidinyl, thienenopyridyl, acridineyl, benzoindolyl, carbazole, biphenylfuranyl, phenanthrololinyl, phenanthidyl, phenpyrazinyl, phenazinyl, phenthiazinyl, phenoxazinyl, xanthonyl, , , , , , , , , and .

[0058] The term "heteroaryl" refers to a divalent heteroaryl group formed by further substitution of one hydrogen atom of a cycloalkyl group, wherein the heteroaryl group may be optionally substituted or unsubstituted, as defined above.

[0059] The term "heteroalkyl" refers to a stable straight-chain or branched, or cyclic, hydrocarbon group, or a combination thereof, consisting of the indicated number of carbon atoms and one or more (one to three in one embodiment) heteroatoms selected from O, N, Si, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen heteroatom may optionally be quaternized. In one embodiment, the heteroatoms O, N, and S may be placed at any internal position within the heteroalkyl group. In one embodiment, the heteroatom Si may be placed at any position within the heteroalkyl group (e.g., internal or terminal positions), including positions where the alkyl group is attached to the remainder of the molecule. Non-limiting examples include: -CH2-CH2-O-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)-CH3, -CH2-S-CH2-CH3, -CH2-CH2-S(O)-CH3, -CH2-CH2-S(O)2-CH3, -CH=CH-O-CH3, -Si(CH3)3, -CH2-CH=N-OCH3, and -CH=CH-N(CH3)-CH3. At most two heteroatoms can be consecutive, for example, -CH2-NH-O-CH3 and -CH2-O-Si(CH3)3. In certain embodiments, the heteroalkyl group is an optionally substituted heteroalkyl group described elsewhere herein.

[0060] The term "alkoxy" refers to -O- (alkyl) and -O- (unsubstituted cycloalkyl), wherein the definition of alkyl or cycloalkyl is as described above. Non-limiting examples of alkoxy groups include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentoxy, or cyclohexyloxy. In one embodiment, the alkoxy group is an optionally substituted alkoxy group as described elsewhere herein.

[0061] The term "alkylacyl" refers to -C(O)-alkyl, where the definition of alkyl is as described above.

[0062] The term "haloalkyl" refers to an alkyl group substituted with one or more halogens, wherein the definition of alkyl is as described above. Non-limiting examples of said haloalkyl groups include: trifluoromethyl, -CH2CF3, or .

[0063] The term “haloalkoxy” refers to an alkoxy group that has been substituted with one or more halogens, where the definition of an alkoxy group is as described above.

[0064] The term "hydroxyalkyl" refers to an alkyl group that has been substituted with a hydroxyl group, where the definition of alkyl is as described above.

[0065] The term "alkathio" refers to -S- (alkyl) and -S- (unsubstituted cycloalkyl), wherein the definition of alkyl or cycloalkyl is as described above. Non-limiting examples of alkathio groups include: methylthio, ethylthio, propylthio, butylthio, cyclopropylthio, cyclobutylthio, cyclopentylthio, or cyclohexylthio. In one embodiment, the alkathio group is an optionally substituted alkathio group described elsewhere herein.

[0066] The term "haloalkylthio" refers to an alkylthio group substituted with one or more halogens, wherein the definition of alkylthio is as described above.

[0067] The term "alkenyl carbonyl" refers to -C(O)-(alkenyl), where alkenyl is defined as previously stated. Non-limiting examples of alkenyl carbonyl include vinyl carbonyl, propenyl carbonyl, or butenyl carbonyl. In one embodiment, the alkenyl carbonyl is an optionally substituted alkenyl carbonyl as described elsewhere herein.

[0068] The term "aminocarbonyl" refers to NH2-C(O)-.

[0069] The term "alkylaminocarbonyl" refers to an aminocarbonyl group (NH2-C(O)-) in which one or both hydrogen atoms are replaced by an alkyl group, wherein the definition of alkyl is as described above.

[0070] The term "alkylamino" refers to an amino group in which one or both of the two hydrogen atoms are replaced by an alkyl group, as defined above.

[0071] The term "carbonyl" refers to the -C(O)-, -(CO)-, or -C(=O)- group. All designations are interchangeable in the specification.

[0072] The term "hydroxyl group" refers to the -OH group.

[0073] The term "halogen" refers to fluorine, chlorine, bromine, or iodine.

[0074] The term "oxo" or "side oxygen" refers to =O.

[0075] The term "hydrogen" includes protons ( 1 H), deuterium ( 2 H), tritium ( 3 H) and / or mixtures thereof. In certain embodiments, one or more hydrogen-occupied sites in the compound may be enriched with deuterium and / or tritium. Such isotope-enriched analogs may be prepared from suitable isotopically labeled starting materials available from commercial sources or by known literature procedures, wherein the hydrogen or hydrogen atom described in this patent comprises its isotopes (H) and / or mixtures thereof. 1 H), deuterium ( 2 H), tritium ( 3 H) and / or mixtures thereof.

[0076] The alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, arylene, heteroaryl, heteroarylene, heteroalkyl, alkoxy, alkylthio, hydroxyalkyl, alkenylcarbonyl, aminocarbonyl, alkylaminocarbonyl, alkylamino, and alkylacyl groups may be substituted or unsubstituted. In one embodiment, the substituent is selected from one or more of the following groups: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, alkylacyl, halogen, mercapto, hydroxyl, nitro, cyano, azide, oxime, phosphate ester, oxo, thio, carboxyl, carboxylic acid ester, cycloalkyl, heterocyclic, aryl, heteroaryl, heterocycloalkoxy, cycloalkylthio, or heterocycloalkylthio.

[0077] The different terms such as "X is selected from A, B, or C", "X is selected from A, B, and C", "X is A, B, or C", and "X is A, B, and C" all express the same meaning, that is, X can be any one or more of A, B, and C.

[0078] "Optional" or "optionally" means that the event or environment described below may but does not have to occur, and the description includes the possibility or absence of such event or environment. For example, "optionally alkyl-substituted heterocyclic group" means that the alkyl group may but does not have to be present, and the description includes cases where the heterocyclic group is substituted with an alkyl group and cases where the heterocyclic group is not substituted with an alkyl group.

[0079] Linking substituents are described in various parts of this invention. When the structure clearly requires a linking group, the Markush variable listed for that group should be understood as the linking group. For example, if the structure requires a linking group and the Markush group definition for that variable lists "alkyl" or "aryl," it should be understood that "alkyl" or "aryl" represents a linked alkylene group or an arylene group, respectively.

[0080] "Substituted" means that any one or more hydrogen atoms on a particular atom are replaced by a substituent, provided that the valence state of the particular atom is normal and the resulting compound is stable. When the substituent is oxo (i.e., =O), it means that two hydrogen atoms are replaced. The term "optionally substituted" means that it may or may not be substituted, and unless otherwise specified, the type and number of substituents can be arbitrary on a chemically feasible basis. It goes without saying that substituents are only in their possible chemical positions, and those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without much effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when combined with a carbon atom having an unsaturated bond (such as an alkene).

[0081] Unless otherwise stated, the indefinite articles “a” and “an” and the definite article “the” in this specification and claims include both plural and singular forms.

[0082] "Pharmaceutical composition" means a mixture containing one or more of the compounds described herein or their physiologically / pharmacologically acceptable salts or prodrugs, along with other chemical components, such as physiologically / pharmacologically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to a living organism, thereby promoting the absorption of the active ingredient and the exertion of its biological activity.

[0083] "Medicinal salts" refer to the salts of the compounds of this invention, which are safe and effective when used in mammals and have the appropriate biological activity.

[0084] "Stereoisomers" encompass all enantiomers / non-corresponding isomers / stereoisomers of the present invention, as well as enantiomers / non-corresponding isomers / stereoisomers enriched in this invention.

[0085] "Stereoisopure" refers to a composition containing one stereoisomer of a compound but substantially lacking another stereoisomer of that compound. For example, a stereoisopure composition of a compound having one chiral center will substantially lack the opposing enantiomer of that compound. A stereoisopure composition of a compound having two chiral centers will substantially lack other diastereomers of that compound. A typical stereoisomeric pure compound comprises, by mass, more than about 80% of one stereoisomer of the compound and less than about 20% of another stereoisomer of the compound; more than about 90% of one stereoisomer of the compound and less than about 10% of another stereoisomer of the compound; more than about 95% of one stereoisomer of the compound and less than about 5% of another stereoisomer of the compound; more than about 97% of one stereoisomer of the compound and less than about 3% of another stereoisomer of the compound; or more than about 99% of one stereoisomer of the compound and less than about 1% of another stereoisomer of the compound.

[0086] "Stereoisomeric enrichment" refers to a composition containing a stereoisomer of a compound at a mass content greater than about 55%, about 60%, about 70%, or about 80%.

[0087] "Enantiomerically pure" refers to a stereoisomerically pure composition of a compound having a single chiral center. Similarly, the term "enantiomerically enriched" refers to a stereoisomerically enriched composition of a compound having a single chiral center.

[0088] "Optical activity" and "enantiomeric activity" refer to a molecular combination having an enantiomer excess of not less than about 50%, not less than about 70%, not less than about 80%, not less than about 90%, not less than about 91%, not less than about 92%, not less than about 93%, not less than about 94%, not less than about 95%, not less than about 96%, not less than about 97%, not less than about 98%, not less than about 99%, not less than about 99.5%, or not less than about 99.8%. In a particular embodiment, the compound comprises about 95% or more of the desired enantiomer or diastereomer by weight of the racemic compound and about 5% or less of the subpreferred enantiomer or diastereomer.

[0089] In describing optically active compounds, the prefixes R and S are used to indicate the absolute configuration of the molecule relative to its chiral center. (+) and (-) are used to indicate the optical rotation of the compound, i.e., the direction of the plane of polarized light rotated by the optically active compound. The prefix (-) indicates that the compound is levorotatory, i.e., the compound rotates the plane of polarized light to the left or counterclockwise. The prefix (+) indicates that the compound is dextrorotatory, i.e., the compound rotates the plane of polarized light to the right or clockwise. However, the signs (+) and (-) for optical rotation are independent of the absolute configuration R and S of the molecule.

[0090] The compounds of this invention include all of their "stereoisomers", "stereoisomeric purity", "stereoisomeric enrichment", "enantiomeric purity", "optical activity", "enantiomeric activity" and "optical isomers". Detailed Implementation

[0091] The present invention is further described below with reference to embodiments, but these embodiments are not intended to limit the scope of the present invention.

[0092] Example The structures of the compounds of this invention were determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR shift ( ) with 10 -6 The unit (ppm) is given. NMR measurements were performed using a Bruker AVANCE-400 NMR spectrometer, with deuterated dimethyl sulfoxide (DMSO) as the solvent. d 6 ), deuterated chloroform (CDCl3), deuterated methanol (CD3OD), with tetramethylsilane (TMS) as the internal standard.

[0093] MS measurements were performed using a Finnigan LCQAd (ESI) mass spectrometer (manufacturer: Thermo, model: Finnigan LCQ advantage MAX).

[0094] The HPLC determination was performed using an Agilent 1200DAD high-performance liquid chromatograph (Sunfire C). 18 150×4.6mm chromatographic column) and Waters 2695-2996 high-performance liquid chromatograph (Gimini C) 18 (150×4.6mm chromatographic column).

[0095] Mean inhibition rate of kinases and IC 50 The values ​​were determined using a NovoStar microplate reader (BMG GmbH, Germany).

[0096] Thin-layer chromatography silica gel plates are Yantai Huanghai HSGF254 or Qingdao GF254. The silica gel plates used in thin-layer chromatography (TLC) have a size of 0.15 mm to 0.2 mm, and the size used for thin-layer chromatography separation and purification of products is 0.4 mm to 0.5 mm.

[0097] Column chromatography typically uses Yantai Huanghai silica gel with a mesh size of 200-300 as the carrier.

[0098] The known starting materials of this invention can be synthesized using or according to methods known in the art, or can be purchased from companies such as ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Accela ChemBio Inc, and Darui Chemicals.

[0099] Unless otherwise specified in the examples, the reactions can be carried out under an argon or nitrogen atmosphere.

[0100] Argon or nitrogen atmosphere refers to a reaction flask connected to an argon or nitrogen gas balloon with a volume of approximately 1L.

[0101] A hydrogen atmosphere refers to a reaction vessel connected to a hydrogen balloon with a volume of approximately 1L.

[0102] The pressurized hydrogenation reaction was performed using a Parr 3916EKX hydrogenator and a Qinglan QL-500 hydrogen generator or an HC2-SS hydrogenator.

[0103] The hydrogenation reaction is usually carried out under vacuum, filled with hydrogen gas, and repeated 3 times.

[0104] The microwave reaction was performed using a CEM Discover-S 908860 microwave reactor.

[0105] Unless otherwise specified in the examples, "solution" refers to an aqueous solution.

[0106] Unless otherwise specified in the examples, the reaction temperature is room temperature, which is 20 ℃ to 30 ℃.

[0107] The reaction process in the examples was monitored using thin-layer chromatography (TLC). The developing solvent systems used in the reactions were: A: dichloromethane and methanol system, B: n-hexane and ethyl acetate system, C: petroleum ether and ethyl acetate system, and D: acetone. The volume ratio of the solvents was adjusted according to the polarity of the compounds.

[0108] The eluent systems for column chromatography and the developing solvent systems for thin-layer chromatography used to purify the compounds include: A: n-hexane and ethyl acetate system, B: n-hexane and tetrahydrofuran system. The volume ratio of the solvents is adjusted according to the polarity of the compounds. Small amounts of basic or acidic reagents such as triethylamine and acetic acid can also be added for adjustment.

[0109] Example 1 4-(1-((1R,5S)-3,8-diazabicyclo[3.2.1]octane-3-yl)-3-((1-((4-(difluoromethylene)piperidin-1-yl)methyl)cyclopropyl)methoxy)-5-fluoro-7,9-dihydrofurano[3,4-f]quinazolin-6-yl)-5-ethynyl-6-fluoronaphthyl-2-phenol Step 1: Preparation of 5-fluoroisobenzofuran-1(3H)-one 2-Bromo-5-fluorobenzyl alcohol (25 g, 121.93 mmol) was dissolved in acetonitrile (150 mL), and Pd(OAc)₂ (2.8 g, 12.4 mmol), Xantphos (10.7 g, 18.5 mmol), and triethylamine (37 g, 365.65 mmol) were added. The mixture was purged with nitrogen and heated to 120°C with stirring for 16 hours under carbon monoxide pressure (10 atm). The reaction mixture was concentrated, extracted with water and ethyl acetate, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography to give E-1-2 (11.3 g, 60.9% yield). MS m / z (ESI): 153 [M+H]. Step 2: Preparation of 4-chloro-5-bromo-6-nitroisobenzofuran-1(3H)-one E-1-2 (11 g, 72.31 mmol) was dissolved in concentrated sulfuric acid (100 mL), heated to 65°C, and nitric acid (11.4 g, 180.92 mmol) was added dropwise, with stirring continuing for 1 hour. After cooling to room temperature, dibromohydantoin (82.7 g, 289.24 mmol) was added in portions, with stirring continuing for 16 hours. The solution was quenched in an ice-water solution of sodium sulfite, extracted with ethyl acetate, and the organic phase was washed with a saturated sodium carbonate solution, followed by washing with water and saturated brine. The solution was dried over anhydrous sodium sulfate, filtered, concentrated, and pulped to obtain E-1-3 (8.7 g, 43.7% yield).

[0110] Step 3: Preparation of 4-bromo-5-fluoro-6-nitro-1,3-dihydroisobenzofuran E-1-3 (8.5 g, 30.79 mmol) was dissolved in dichloromethane (100 mL), cooled to -78°C under nitrogen protection, and DIBAL-H (55 mmol, 55 mL, 1 M in THF) was added. After the addition was complete, the mixture was stirred at -78°C for 3 hours. Quenching with 5N NaOH aqueous solution, extraction with dichloromethane, drying with anhydrous sodium sulfate, filtering, concentrating, and slurrying to obtain crude product (7.6 g), which was dissolved in dichloromethane (100 mL), cooled to 0°C, and triethylsilane (12.8 g, 110.08 mmol) was added. The reaction was continued for 30 minutes, and trifluoroacetic acid (6.2 g, 54.38 mmol) was added at 0°C. The mixture was gradually heated to room temperature and stirred for 16 hours, concentrated, diluted with ethyl acetate, washed with saturated sodium bicarbonate aqueous solution, then washed with water and saturated brine, dried with anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography to obtain E-1-4 (4.2 g, yield 52.1%).

[0111] Step 4: Preparation of 7-bromo-6-fluoro-1,3-dihydroisobenzofuran-5-amine E-1-4 (4 g, 15.27 mmol) was dissolved in ethanol / water (100 mL / 20 mL), ammonium chloride (4.9 g, 91.61 mmol) and iron powder (5.1 g, 91.32 mmol) were added, and the mixture was heated to 80°C and stirred for 16 hours. The mixture was filtered through diatomaceous earth, washed with ethanol, concentrated the organic phase, extracted with water and ethyl acetate, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography to obtain E-1-5 (3.1 g, 87.6% yield). MS m / z (ESI): 232 [M+H]. Step 5: Preparation of ethyl N-[(7-bromo-6-fluoro-1,3-dihydroisobenzofuran-5-yl)aminomethylthionyl]carbamate E-1-5 (3 g, 12.93 mmol) was dissolved in dichloromethane (100 mL), and ethyl isothiocyanate (2.1 g, 16.01 mmol) was slowly added dropwise. The mixture was stirred at room temperature for 5 hours. The solution was filtered, the filter cake was washed with dichloromethane, the organic phase was concentrated, and purified by silica gel column chromatography to obtain E-1-6 (4.5 g, 95.7% yield). MS m / z (ESI): 363 [M+H]. Step 6: Preparation of ethyl(Z)-(((7-bromo-6-fluoro-1,3-dihydroisobenzofuran-5-yl)amino)(ethylthio)methylene)carbamate Potassium carbonate (6.2 g, 44.86 mmol) was added to a 100 mL solution of E-1-6 (4.5 g, 12.39 mmol) in acetone at room temperature, followed by the dropwise addition of iodoethane (2.34 g, 15.0 mmol). The mixture was stirred at room temperature for 16 hours. The solid was filtered, washed with acetone, and purified by silica gel column chromatography after concentration of the organic phase to obtain E-1-7 (4.6 g, 94.8% yield). MS m / z (ESI): 391 [M+H]. Step 7: Preparation of 6-bromo-3-(ethio)-5-fluoro-7,9-dihydrofurano[3,4-f]quinazolin-1-ol E-1-7 (4.5 g, 11.50 mmol) was dissolved in NMP (30 mL) and added dropwise to a 100 mL NMP solution preheated to 175°C under nitrogen protection. After the addition was complete, the reaction continued for 30 minutes, then gradually cooled to 45°C. Water (150 mL) was added, and the mixture was stirred for 1 hour. After cooling to room temperature, the mixture was filtered, the filter cake was washed with water, and the solid was dried to give E-1-8 (3.1 g, yield 78.1%). MS m / z (ESI): 345 [M+H]. Step 8: Preparation of 6-bromo-1-chloro-3-(ethio)-5-fluoro-7,9-dihydrofurano[3,4-f]quinazoline E-1-8 (3 g, 8.69 mmol) was dissolved in acetonitrile (80 mL). Under nitrogen purging protection, DIPEA (1.3 g, 10.1 mmol) was added. The reaction solution was cooled to 0°C, and POCl3 (7 mL) was added dropwise. The mixture was stirred at 0°C for 10 minutes, then heated to 110°C and stirred for 3 hours. The reaction solution was concentrated to obtain crude E-1-9 (4.5 g), which was used directly in the next reaction. MS m / z (ESI): 363 [M+H]. Step 9: Preparation of tert-butyl(1R,5S)-3-(6-bromo-3-(ethio)-5-fluoro-7,9-dihydrofurano[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid ester E-1-9 (4.5 g) was dissolved in dichloromethane (50 mL), and DIPEA (5.2 g, 40.24 mmol) was added. The mixture was stirred for 10 minutes under nitrogen purging protection. Then, tert-butylrac-(1R,5S)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid ester (3.18 g, 14.98 mmol) was added, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated, water was added, and the mixture was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography to obtain the target compound E-1-10 (3.7 g, two-step yield 78.9%). MS m / z (ESI): 539 [M+H]. Step 10: Preparation of tert-butyl(1R,5S)-3-(6-bromo-3-(ethylsulfonyl)-5-fluoro-7,9-dihydrofurano[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid ester At 0°C, m-chloroperoxybenzoic acid (510 mg, 2.51 mmol, 85% purity) was added to a 30 mL solution of E-1-10 (500 mg, 0.93 mmol) in dichloromethane. The mixture was stirred at room temperature for 30 minutes after the addition was complete. The reaction solution was directly concentrated and purified by silica gel column chromatography to obtain E-1-11 (340 mg, 64.2% yield). MS m / z (ESI): 571 [M+H]. Step 11: Preparation of tert-butyl(1R,5S)-3-(6-bromo-3-((1-((4-(difluoromethylene)piperidin-1-yl)methyl)cyclopropyl)methoxy)-5-fluoro-7,9-dihydrofurano[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid ester At 0°C, a solution of E-1-11 (330 mg, 0.63 mmol) and [1-[[4-(difluoromethylene)-1-piperidinyl]methyl]cyclopropyl]methanol (540 mg, 2.49 mmol) in tetrahydrofuran (20 mL) was added, followed by the addition of sodium hydroxide (110 mg, 2.75 mmol, 60% purity). The mixture was stirred at room temperature for 1 hour after the addition was complete. The reaction solution was quenched with aqueous ammonium chloride solution, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography to obtain E-1-12 (375 mg, 93.5% yield). MS m / z (ESI): 694 [M+H]. Step 12: Preparation of tert-butyl(1R,5S)-3-(3-((1-((4-(difluoromethylene)piperidin-1-yl)methyl)cyclopropyl)methoxy)-5-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphth-1-yl)-7,9-dihydrofurano[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid ester E-1-12 (360 mg, 0.52 mmol), 2-[2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxyborane-2-yl)-1-naphthyl]ethynyltriisopropylsilane (340 mg, 0.66 mmol), methanesulfonic acid [n-butyldi(1-adamantyl)phosphine](2-amino-1,1'-biphenyl-2-yl)palladium(II)(II) (60 mg, 0.08 mol), and aqueous sodium hydroxide solution (2 M, 0.5 mL) in tetrahydrofuran (5 mL) were microwaved at 100°C for 1 hour. Ammonium chloride solution was added, and the mixture was extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography to give E-1-13 (390 mg, 75.3% yield).

[0112] Step 13: Preparation of tert-butyl(1R,5S)-3-(3-((1-((4-(difluoromethylene)piperidin-1-yl)methyl)cyclopropyl)methoxy)-6-(8-ethynyl-7-fluoro-3-(methoxymethoxy)naphth-1-yl)-5-fluoro-7,9-dihydrofurano[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid ester To a solution of E-1-13 (380 mg, 0.38 mmol) in tetrahydrofuran (20 mL), add tetrabutylammonium fluoride tetrahydrofuran solution (1 M, 2 mL), and stir at room temperature for 30 minutes. Add water, extract with ethyl acetate, wash the organic phase with water, dry to anhydrous sodium sulfate, filter, concentrate, and purify by silica gel column chromatography to obtain E-1-14 (210 mg, yield 65.4%). MS m / z (ESI): 844 [M+H]. Step 14: Preparation of 4-(1-((1R,5S)-3,8-diazabicyclo[3.2.1]octane-3-yl)-3-((1-((4-(difluoromethylene)piperidin-1-yl)methyl)cyclopropyl)methoxy)-5-fluoro-7,9-dihydrofurano[3,4-f]quinazolin-6-yl)-5-ethynyl-6-fluoronaphthyl-2-phenol At 0°C, a solution of dichloromethane (10 mL) and methanol (2 mL) containing E-1-14 (200 mg, 0.24 mmol) was added, followed by the addition of dioxane hydrochloride solution (4 M, 2 mL). The mixture was stirred at room temperature for 1 hour after the addition was complete. The reaction solution was then slowly added to an aqueous sodium bicarbonate solution, extracted with dichloromethane / methanol (v / v = 10 / 1), the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by high-performance liquid chromatography to obtain Example 1 (86 mg, yield 51.9%). MS m / z (ESI): 700 [M+H]. The synthesis of Examples 2-11 follows the same method as in Example 1: Alternatively, Example 11 was prepared using the following method: Example 11 2-Amino-4-(3-(1-(4-(difluoromethylene)piperidin-1-yl)methyl)cyclopropyl)methoxy)-5-fluoro-1-(((R)-1-methyl-2-oxoperidin-3-yl)amino)-7,9-dihydrofurano[3,4-f]quinazolin-6-yl)-7-fluorobenzothiophene-3-onitrile Step 1: Combine intermediate E-1-9 (400 mg, 1.1 mmol) and N , NDiisopropylethylamine (853 mg, 6.6 mmol) was dissolved in dichloromethane (20 mL) and stirred at 35 °C for 2 hours. The reaction solution was cooled, concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography to give (3R)-3-[(6-bromo-3-ethylthioalkyl-5-fluoro-7,9-dihydrofurano[3,4-f]quinazolin-1-yl)amino]-1-methylpiperidin-2-one (500 mg, 99.8% yield). MS m / z (ESI): 455 [M+H]. Step 2: Compound 11-1 (500 mg, 1.1 mmol) was dissolved in dichloromethane (15 mL) at 0 °C, and m-chloroperoxybenzoic acid (208 mg, 1.2 mmol, 85% purity) was added. The mixture was stirred at 0 °C for 1 hour, and the reaction solution was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to obtain (3R)-3-[(6-bromo-3-ethylsulfinyl-5-fluoro-7,9-dihydrofurano[3,4-f]quinazolin-1-yl)amino]-1-methylpiperidin-2-one (420 mg, yield 81.1%). MS m / z (ESI): 471 [M+H]. Step 3: Compound 11-2 (420 mg, 890.1 μmol) and (1-((4-(difluoromethylene)piperidin-1-yl)methyl)cyclopropyl)methanol (390 mg, 1.8 mmol) were dissolved in tetrahydrofuran (20 mL), and sodium hydride (356 mg, 8.9 mmol, 60% purity) was added. The mixture was stirred at 60 °C for 1 hour. The reaction solution was cooled and quenched in a saturated ammonium chloride aqueous solution. The organic phase was collected, and the aqueous phase was extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography to give (3R)-3-[[6-bromo-3-[[1-[[4-(difluoromethylene)-1-piperidinyl]methyl]cyclopropyl]methoxy]-5-fluoro-7,9-dihydrofurano[3,4-f]quinazolin-1-yl]amino]-1-methylpiperidin-2-one (500 mg, yield 91.9%). MS m / z (ESI): 610 [M+H]. Step 4: At room temperature, compound 11-3 (500 mg, 890.1 μmol), tert-butyl(3-cyano-4-(5,5-dimethyl-1,3,2-dioxaboro-2-yl)-7-fluorobenzo[B]thiophene-2-yl)carbamate (646 mg, 1.6 mmol), cesium carbonate (815 mg, 2.5 mmol), and bis(diphenylphosphine ether)palladium(II) dichloride (58 mg, 80.8 μmol) were mixed in toluene (20 mL) and stirred at 120 °C for 3 hours under nitrogen protection. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography to obtain...N -[3-cyano-4-[3-[[1-[[4-(difluoromethylene)-1-piperidinyl]methyl]cyclopropyl]methoxy]-5-fluoro-1-[[(3R)-1-methyl-2-oxo-3-piperidinyl]amino]-7,9-dihydrofurano[3,4-f]quinazolin-6-yl]-7-fluoro-benzothiophene-2-yl]tert-butyl carbamate (400 mg, yield 59.4%). MS m / z (ESI): 822 [M+H]. Step 5: Compound 11-4 (400 mg, 486.7 μmol) was dissolved in dichloromethane (5 mL), and trifluoroacetic acid (560 mg, 4.8 mmol) was added. The mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, and the crude product was separated by high performance liquid chromatography to obtain Example 11 (5 mg, first eluting isomer). MS m / z (ESI): 722 [M+H]. 1 H NMR (400 MHz, DMSO- d 6) δ 8.10 (s, 2H), 7.35 (dd, J = 8.4, 5.3 Hz, 1H), 7.12 (dd, J = 9.5, 8.4 Hz, 1H), 6.96 (d, J = 6.4 Hz, 1H), 5.64 – 5.51(m, 2H), 4.96 – 4.85 (m, 1H), 4.74 – 4.58 (m, 2H), 4.23 (s, 2H), 3.43 – 3.26(m, 2H), 2.91 (s, 3H), 2.48 – 2.30 (m, 7H), 2.18 – 2.07 (m, 4H), 2.01 – 1.91 (m, 3H), 0.66 (s, 2H), 0.42 (s, 2H). Example 13 2-Amino-4-(3-((1-(4-(difluoromethylene)piperidin-1-yl)methyl)cyclopropyl)methoxy)-5-fluoro-1-((R)-1-methyl-2-oxopiridine-3-yl)amino)-7,9-dihydrofuran[3,4-f]quinazolin-6-yl)-7-fluorothieno[3,2-c]pyridine-3-nitrile The synthesis of Example 13 was performed using the same method as in Example 1 or Example 11. MS m / z (ESI): 723 [M+H]. 1 H NMR (400 MHz, DMSO- d 6) δ 8.45 (s, 2H), 8.41 (s, 1H), 6.92 (dd, J =13.9, 6.2 Hz, 1H), 5.75 – 5.47 (m, 2H), 5.16 – 4.96 (m, 1H), 4.83 – 4.69 (m,1H), 4.65 – 4.48 (m, 1H), 4.31 – 4.14 (m, 2H), 3.50 – 3.45 (m, 2H), 2.91 (d, J = 2.6 Hz, 3H), 2.47 – 2.40 (m, 5H), 2.39 – 2.26 (m, 2H), 2.12 (t, J = 5.6Hz, 4H), 2.02 – 1.90 (m, 4H), 0.67 (d, J = 5.6 Hz, 2H), 0.41 (d, J = 4.9 Hz, 2H). Example 17 2-Amino-4-(3-((1-(4-(difluoromethylene)piperidin-1-yl)methyl)cyclopropyl)methoxy)-5-fluoro-1-((R)-1-methyl-2-oxopyrrolidine-3-yl)amino)-7,9-dihydrofuran[3,4-f]quinazolin-6-yl)-7-fluorothieno[3,2-c]pyridine-3-nitrile The synthesis of Example 17 was performed following the synthesis method of Example 1 or Example 11. MS m / z (ESI): 709 [M+H]. 1 H NMR (400 MHz, DMSO- d 6) δ 9.16(s, 1H), 8.45 (s, 1H), 8.42 (s, 1H),6.90 (t, J = 7.6 Hz, 1H), 5.75 – 5.46 (m, 2H), 5.12 – 5.01 (m, 1H), 4.74 (d, J= 12.5 Hz, 1H), 4.41 – 4.13 (m, 2H), 3.85 – 3.65 (m, 2H), 3.47 – 3.38 (m,3H), 3.29 – 3.18 (m, 2H), 3.06 – 2.90 (m, 2H), 2.82(d, J = 3.1 Hz, 3H), 2.66– 2.55 (m, 2H), 2.47 – 2.29 (m, 3H), 2.21 – 2.08 (m, 1H), 0.95 – 0.83 (m,2H), 0.81 – 0.65 (m, 2H). The synthesis of Examples 12-46 follows the same method as in Example 1 or Example 11: Example 47 2-Amino-4-(1-(((R)-1-(3,3-difluoroazacyclobutane-1-yl)-1-oxopropyl-2-yl)amino)-3-((1-(4-(difluoromethylene)piperidin-1-yl)methyl)cyclopropyl)methoxy)-5-fluoro-7,9-dihydrofurano[3,4-f]quinazolino-6-yl)-7-fluorobenzothiophene-3-nitrile Step 1: At room temperature, add to a solution of compound 47-1 (1.0 g, 5.3 mmol), 3,3-difluorotrimethylimine hydrochloride (825 mg, 6.3 mmol), and 1-butylphosphine anhydride (4.6 g, 6.3 mmol, 50% ethyl acetate solution) in dichloromethane (20 mL) N,N -Diisopropylethylamine (2.0 g, 15.9 mmol) was stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography to give (R)-(1-(3,3-difluoroazacyclobutan-1-yl)-1-oxopropyl-2-yl)tert-butyl carbamate (1.2 g, 85.9% yield). MS m / z (ESI): 265 [M+H]. Step 2: At room temperature, compound 47-2 (1.2 g, 4.5 mmol) was dissolved in dichloromethane (20 mL), and trifluoroacetic acid (10 mL) was added. The mixture was stirred at room temperature for 1 hour. The solution was concentrated under reduced pressure to give (R)-2-amino-1-(3,3-difluoroazacyclobutan-1-yl)prop-1-one (700 mg, 93.9% yield). MS m / z (ESI): 165 [M+H]. Step 3: At room temperature, compound 47-3 (164 mg, 1.0 mmol) and intermediate A (300 mg, 0.8 mmol) were dissolved in dichloromethane (10 mL), and then added... N,N -Diisopropylethylamine (320 mg, 2.5 mmol) was stirred at 35 °C for 16 hours. The reaction solution was extracted with ethyl acetate, the organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel column chromatography to give (R)-2-((6-bromo-3-(ethylthio)-5-fluoro-7,9-dihydrofurano[3,4-f]quinazolin-1-yl)amino)-1-(3,3-difluoroazacyclobutan-1-yl)prop-1-one (400 mg, 98.7% yield). MS m / z (ESI): 491 [M+H]. Step 4: At room temperature, compound 47-4 (400 mg, 0.8 mmol) was dissolved in dichloromethane (10 mL), and m-chloroperoxybenzoic acid (480 mg, 2.4 mmol, 85% purity) was added. The mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography to give (R)-2-((6-bromo-3-(ethylsulfonyl)-5-fluoro-7,9-dihydrofurano[3,4-f]quinazolin-1-yl)amino)-1-(3,3-difluoroazacyclobutane-1-yl)prop-1-one (400 mg, yield 96.9%). MS m / z (ESI): 523 [M+H]. Step 5: At room temperature, sodium hydride (92 mg, 3.8 mmol, 60% purity) was added to a tetrahydrofuran (10 mL) solution of compound 47-5 (400 mg, 0.8 mmol) and (1-((4-(difluoromethylene)piperidin-1-yl)methyl)cyclopropyl)methanol (332 mg, 1.5 mmol), and the mixture was stirred at 50°C for 1 hour. The reaction solution was poured into a saturated ammonium chloride aqueous solution, extracted with ethyl acetate, and the organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel column chromatography to give (R)-2-((6-bromo-3-(1-(4-(difluoromethylene)piperidin-1-yl)methyl)cyclopropyl)methoxy)-5-fluoro-7,9-dihydrofurano[3,4-f]quinazolin-1-yl)amino)-1-(3,3-difluoroazacyclobutan-1-yl)prop-1-one (400 mg, yield 81.0%). MS m / z (ESI): 646 [M+H]. Step 6: At room temperature, add bis(diphenylphosphine ether) palladium dichloride (89 mg, 0.1 mmol) and cesium carbonate (605 mg, 1.9 mmol) to a toluene (10 mL) solution of compound 47-6 (400 mg, 0.6 mmol), tert-butyl-3-cyano-4-(5,5-dimethyl-1,3,2-dioxaboronic-2-yl)-7-fluorobenzo[B]thiophene-2-yl)carbamate (500 mg, 1.2 mmol), and stir at 110 °C for 2 hours under nitrogen protection. The reaction solution was filtered and concentrated. The crude product was purified by silica gel column chromatography to obtain tert-butyl (3-cyano-4-(1-(((R)-1-(3,3-difluoroazacyclobutane-1-yl)-1-oxopropyl-2-yl)amino)-3-((1-(4-(difluoromethylene)piperidin-1-yl)methyl)cyclopropyl)methoxy)-5-fluoro-7,9-dihydrofurano[3,4-f]quinazolino-6-yl)-7-fluorobenzo[b]thiophene-2-yl)carboxylate (350 mg, yield 65.9%). MS m / z (ESI): 858 [M+H]. Step 7: At room temperature, trifluoroacetic acid (3 mL) was added to a solution of compound 47-7 (350 mg, 0.4 mmol) in dichloromethane (9 mL), and the mixture was stirred at room temperature for 1 hour. The solution was concentrated under reduced pressure, and the crude product was separated by high-performance liquid chromatography (HPLC) to obtain Example 47 (80 mg). MS m / z (ESI): 758 [M+H]. 1 H NMR (400 MHz, DMSO- d 6) δ 9.17 (s, 1H), 8.11 (s, 1H), 7.27 (dd, J =8.4, 5.2 Hz, 1H), 7.13 (t, J = 8.4 Hz, 1H), 6.76 (s, 1H), 5.75 (d, J = 12.5Hz, 1H), 5.61 (d, J = 12.5 Hz, 1H), 4.90 (d, J = 12.7 Hz, 2H), 4.75 (d, J =12.7 Hz, 2H), 4.62 (s, 1H), 4.50 – 4.12 (m, 4H), 3.74 (d, J= 31.3 Hz, 1H),3.26 (s, 2H), 2.98 (s, 1H), 2.59 (s, 1H), 2.46 – 2.29 (m, 3H), 2.12 (s, 1H),2.00 (q, J = 6.9 Hz, 1H), 1.48 (d, J = 6.9 Hz, 3H), 0.96 – 0.82 (m, 2H), 0.76(s, 2H). The synthesis of Examples 48-102 follows the same method as in Example 11 or Example 47: Example 103 2-Amino-4-(1-(((R)-1,1-dioxytetrahydrothiophene-3-yl)amino)-5-fluoro-3-((1-(morpholinomethyl)cyclopropyl)methoxy)-7,9-dihydrofuran[3,4-f]quinazolin-6-yl)-7-fluorobenzo[b]thiophene-3-nitrile Step 1: At room temperature, diisopropylethylamine (11.0 g, 85.0 mmol) and (3R)-1,1-dioxothiol-3-amine hydrochloride (7.3 g, 42.5 mmol) were added to a 200 mL solution of intermediate E-1-9 (17.0 g, 42.5 mmol) in tetrahydrofuran. The mixture was stirred at 50 °C for 4 hours. The reaction solution was concentrated under reduced pressure. The crude product was slurried with water, filtered, and the filter cake was dried. The slurry was then slurried with petroleum ether / ethyl acetate (5:1), filtered, and the filter cake was dried to obtain 6-bromo- N -[(3R)-1,1-dioxothioheptan-3-yl]-3-ethylthioalkyl-5-fluoro-7,9-dihydrofurano[3,4-f]quinazolin-1-amine (11.0 g, yield 53.2%). MS m / z (ESI): 461 [M+H]. Step 2: Compound 103-1 (1.0 g, 2.2 mmol) was dissolved in dichloromethane (15 mL) at 0 °C, and m-chloroperoxybenzoic acid (1.5 g, 7.6 mmol, 85% purity) was added. The mixture was stirred at 0 °C for 1 hour. The reaction solution was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography to give (R)-3-((6-bromo-3-(ethanesulfonyl)-5-fluoro-7,9-dihydrofurano[3,4-f]quinazolin-1-yl)amino)tetrahydrothiophene 1,1-dioxide (770 mg, yield 72.0%). MS m / z (ESI): 495 [M+H]. Step 3: Compound 103-2 (700 mg, 1.4 mmol) and [1-(morpholinomethyl)cyclopropyl]methanol (364 mg, 2.1 mmol) were dissolved in tetrahydrofuran (20 mL), and sodium hydride (283 mg, 7.1 mmol, 60% purity) was added. The mixture was stirred at 60 °C for 1 hour. The reaction solution was cooled, quenched in a saturated ammonium chloride aqueous solution, extracted with ethyl acetate, and the organic phase was collected. The solution was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography to give (R)-3-((6-bromo-5-fluoro-3-((1-(morpholinomethyl)cyclopropyl)methoxy)-7,9-dihydrofurano[3,4-f]quinazolin-1-yl)amino)tetrahydrothiophene 1,1-dioxide (500 mg, yield 61.8%). MS m / z (ESI): 572 [M+H]. Step 4: At room temperature, compound 103-3 (500 mg, 875 μmol), tert-butyl(3-cyano-4-(5,5-dimethyl-1,3,2-dioxaboronic-2-yl)-7-fluorobenzo[B]thiophene-2-yl)carbamate (707 mg, 1.8 mmol), cesium carbonate (856 mg, 2.6 mmol), and bis(diphenylphosphine ether)palladium(II) dichloride (58 mg, 80.8 μmol) were added to toluene (20 μmol). The mixture was stirred at 120°C for 3 hours under nitrogen protection, cooled to room temperature, concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography to obtain tert-butyl(3-cyano-4-(1-((((R)-1,1-thiopyrocyclopentan-3-yl)amino)-5-fluoro-3-((1-(morpholinomethyl)cyclopropyl)methoxy)-7,9-dihydrofurano[3,4-f]quinazolin-6-yl)-7-fluorobenzo[b]thiophene-2-yl)carboxamide (500 mg, yield 73.0%). MS m / z (ESI): 783 [M+H]. Step 5: Compound 103-4 (500 mg, 638.7 μmol) was dissolved in dichloromethane (5 mL), and trifluoroacetic acid (0.5 mL) was added. The mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, and the crude product was separated by high performance liquid chromatography to obtain Example 103 (61 mg, first eluting isomer). MS m / z (ESI): 683 [M+H]. 1 H NMR (400 MHz, DMSO- d 6) δ 8.11 (s, 2H), 7.28 (dd, J = 8.4, 5.2 Hz, 1H), 7.12 (t, J = 8.8 Hz, 1H), 6.60 (d, J = 7.0 Hz, 1H), 5.74 – 5.51 (m, 2H), 5.03 (d, J = 7.6 Hz, 1H), 4.93 (d, J = 12.4 Hz, 1H), 4.73 (d, J = 12.4 Hz,1H), 4.37 – 4.17 (m, 2H), 3.58 (dt, J = 19.6, 6.0 Hz, 5H), 3.46 – 3.38 (m,1H), 3.27 (dd, J = 12.8, 8.0 Hz, 1H), 2.57 (t, J = 6.5 Hz, 1H), 2.47 – 2.21(m, 7H), 0.65 (s, 2H), 0.42 (s, 2H). The synthesis of Examples 104-146 follows the same synthesis method as in Example 47 or Example 103: Biological testing evaluation The present invention will be further described and explained below with reference to test examples, but these embodiments are not intended to limit the scope of the present invention.

[0113] I. Determination of the inhibitory activity of the compounds of this invention against the proliferation of KRAS-mutated and expanded tumor cell lines 1. Experimental objective: To determine the inhibitory activity of the compounds in the examples on the proliferation of KRAS mutant and amplified cell lines SW620 and MKN1.

[0114] 2. Experimental instruments: nano-level dispensing system (I-DOT); microplate reader (BioTek Synergy H1); pipettes (Eppendorf & Rainin).

[0115] 3. Experimental Reagents: MKN1 cells were purchased from Nanjing Kebai Biotechnology Co., Ltd.; SW620 cells were purchased from ATCC; Cell Titer-Glo was purchased from Promega (Catalog No. G7573); RPMI 1640 was purchased from Gibco (Catalog No. 22400089); DMEM was purchased from Gibco (Catalog No. 11995065); FBS was purchased from Gibco (Catalog No. 10091148); PBS was purchased from Gibco (Catalog No. 10010023); trypsin was purchased from Gibco (Catalog No. 25200056); and cell culture plates were purchased from Corning (Catalog No. 3610).

[0116] 4. Experimental Methods: When SW620 and MKN1 cells reached a suitable confluence, cells were collected and adjusted to a suitable cell density using complete culture medium. The cell suspension was then seeded into 96-well plates at 100 μL per well and incubated overnight at 37°C with 5% CO2. Compound solutions of different concentrations were prepared using DMSO, and then the compound solutions were added to the 96-well plates using the I-DOT nanoliter separatory system at 8 nL-600 nL per well. After incubation at 37°C with 5% CO2 for 3-6 days, 50 μL of CellTiter-Glo solution was added, the mixture was shaken to mix thoroughly, and incubated in the dark for 10 minutes. The readings were then taken using a BioTek Synergy H1 microplate reader.

[0117] 5. Experimental Data Processing Methods: The inhibition rate was calculated using the emission signal value. The concentration and inhibition rate were then fitted with a nonlinear regression curve using Graphpad Prism software to obtain the IC50. 50 value.

[0118] 6. Experimental Results: Table 1: Inhibitory activity of compounds against the proliferation of KRAS-mutant tumor cell lines SW620 and MKN1 7. Experimental Conclusion: The compounds in the embodiments of the present invention have significant inhibitory effects on the proliferation of SW620 and MKN1 cells.

[0119] II. Determination of the inhibitory activity of the compounds of this invention on the proliferation of KRAS G12D mutant tumor cell lines 1. Experimental objective: To determine the inhibitory activity of the compounds in the examples on the proliferation of five KRAS G12D mutant cell lines: SNU-1, HPAF-II, Panc0403, AsPC-1, and GP2D.

[0120] 2. Experimental instruments: Microplate reader (BioTek Synergy H1); pipettes (Eppendorf & Rainin).

[0121] 3. Experimental reagents: HPAF-II, PANC0403, AsPC-1, and GP2D were purchased from Nanjing Kebai Biotechnology Co., Ltd.; SNU-1 was purchased from the Cell Bank of the Chinese Academy of Sciences; Cell Titer-Glo was purchased from Promega (Catalog No. G7573); RPMI 1640 was purchased from Gibco (Catalog No. 22400089); DMEM was purchased from Gibco (Catalog No. 11995065); FBS was purchased from Gibco (Catalog No. 10091148); PBS was purchased from Gibco (Catalog No. 10010023); trypsin was purchased from Gibco (Catalog No. 25200056); and cell culture plates were purchased from Corning (Catalog No. 3610).

[0122] 4. Experimental Methods: When SNU-1, HPAF-II, Panc0403, AsPC-1, or GP2D cells reached a suitable confluence, collect the cells and adjust them to a suitable cell density using complete culture medium. Spread the cell suspension into 96-well plates, 90 μL per well, and incubate overnight at 37°C with 5% CO2. Prepare compound solutions of different concentrations using DMSO and culture medium, and set up a solvent control. Add 10 μL of the compound solution to each well of the 96-well plate and incubate at 37°C with 5% CO2 for approximately 72 hours. Then add CellTiter-Glo solution, shake to mix thoroughly, and incubate in the dark for 10 minutes. Read the values ​​using a BioTek Synergy H1 microplate reader.

[0123] 5. Experimental Data Processing Methods: The inhibition rate was calculated using the emission signal value. The concentration and inhibition rate were then fitted using Graphpad Prism software to obtain the EC50. 50 value.

[0124] 6. Experimental Results Table 2: Inhibitory activity of compounds against the proliferation of KRAS G12D mutant tumor cell lines 7. Experimental conclusion: The compound of the embodiment of the present invention has significant proliferation inhibitory effects on SNU-1, HPAF-II, Panc0403, AsPC-1 and GP2D cells.

[0125] III. Mouse Pharmacokinetics Determination 1 Experimental purpose: Using Balb / c mice as the test animals, to study the pharmacokinetic behavior of the compound after oral administration in mice (plasma).

[0126] 2 Test protocol: 2.1 Test drug: The compound of the embodiment of the present invention, self-made.

[0127] 2.2 Test animals: Balb / c mice, male, purchased from Shanghai Jiesijie Laboratory Animal Co., Ltd., animal production license number (SCXK (Shanghai) 2013-0006 N0.311620400001794).

[0128] 2.3 Drug preparation: Oral administration drug preparation: 10% Captisol in 50 mM citrate buffer pH5.0 Preparation of 50mM citric acid: Weigh 4.8g of citric acid into a 1000ml glass bottle, add ultrapure water to 300ml, stir magnetically to completely dissolve it, and supplement ultrapure water to 500ml to prepare 50mM citric acid.

[0129] Preparation of 50mM citric acid (10% Captisol, PH = 5): Weigh 50g of Captisol powder, add it to a 1000ml glass bottle, add 300ml of 50mM citric acid, stir magnetically to completely dissolve it, supplement citric acid to 500ml, and adjust the PH = 5 with 10M NaOH. Weigh the compound of the embodiment, add it to a 4-mL glass bottle respectively, add 2.4 mL of this solution, and ultrasonicate for 10 minutes to obtain a colorless and clear solution with a concentration of 3 mg / mL.

[0130] 2.4 Administration: 3 Balb / c mice, male; after fasting overnight, they were orally administered respectively at a dose of 30 mg / kg and a dosing volume of 10mL.

[0131] 2.5 Sample collection: 0.04 mL of orbital blood was collected before administration and at 0.25 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 24 h after administration. The blood was placed in an EDTA-2K test tube, centrifuged at 6000 rpm for 6 min at 4°C to separate plasma, and stored at -20°C; they were fed 4 h after administration.

[0132] 3 Experimental results: Table 3: Pharmacokinetic parameters of mice 4. Experimental conclusion: The compound of the embodiment of the present invention has a high oral exposure amount.

[0133] III. Pharmacokinetic determination of rats 1 Experimental purpose: Using SD rats as test animals, study the pharmacokinetic behavior of the compound of the embodiment by oral administration in rats (plasma).

[0134] 2 Test plan: 2.1 Test drug: The compound of the present invention, self-made.

[0135] 2.2 Test animals: 3 male SD rats in each group. Shanghai Jiesijie Experimental Animal Co., Ltd., Animal Production License No. (SCXK (Shanghai) 2013-0006 N0.311620400001794).

[0136] 2.3 Drug preparation: Oral administration drug preparation: 10% Captisol in 50 mM citrate buffer pH5.0 Preparation of 50mM citric acid: Weigh 4.8g of citric acid into a 1000ml glass bottle, add ultrapure water to 300ml, stir magnetically to completely dissolve it, and supplement ultrapure water to 500ml to prepare 50mM citric acid.

[0137] Preparation of 50mM citric acid (10% Captisol, PH = 5): Weigh 50g of Captisol powder, add it to a 1000ml glass bottle, add 300ml of 50mM citric acid, stir magnetically to completely dissolve it, supplement citric acid to 500ml, and adjust the PH = 5 with 10M NaOH.

[0138] Weigh the compound of the embodiment and dissolve it in this solution, shake well, and ultrasonic for 15 minutes to obtain a colorless and clear solution with a concentration of 3mg / mL.

[0139] 2.4 Administration: 3 male SD rats in each group; after fasting overnight, they were orally administered respectively, with a dose of 30 mg / kg and a dosing volume of 10 mL.

[0140] 2.5 Sample collection: 0.2 mL of jugular vein blood was collected before administration and at 0.25h, 0.5 h, 1.0 h, 2.0 h, 4.0 h, 6.0 h, 8.0h, 24.0 h after administration, placed in an EDTA-2K test tube, centrifuged at 4°C at 6000 rpm for 6 minutes to separate plasma, and stored at -20°C; they were allowed to eat 4 h after administration.

[0141] 3. Experimental Results: Table 4: Pharmacokinetic parameters in rats 4. Experimental conclusion: The compounds in the embodiments of the present invention have high oral exposure levels.

[0142] IV. In vivo pharmacodynamic study of a subcutaneous xenograft model of human lung adenocarcinoma cell line NCI-H441 in nude mice 1. Experimental objective: To evaluate the in vivo efficacy of the compound in a human lung adenocarcinoma NCI-H441 subcutaneous xenograft model in nude mice.

[0143] 2. Experimental reagents: RPMI-1640 medium (22400-089, Gibco); fetal bovine serum (FBS) (10099-141C, Gibco); phosphate-buffered saline (PBS) (10010-023, Gibco); Kolliphor HS15 (42966-1KG, Sigma-Aldrich); methylcellulose M450 (69016482, Sinopharm Reagent); Tween-80 (30189828, Sinopharm Reagent).

[0144] 3. Experimental procedures and data processing: 3.1 Animals: BALB / c nude mice, 6-8 weeks old, female, purchased from Vital River.

[0145] 3.2 Cell Culture and Cell Suspension Preparation a) Take one NCI-H441 cell line from the cell bank, revive the cells with RPMI-1640 medium (RPMI-1640 + 10% FBS), and place the revive cells in a cell culture flask (label the flask wall with cell type, date, culturer's name, etc.) and place it in a CO2 incubator (incubator temperature is 37℃, CO2 concentration is 5%).

[0146] b) Pass the cells every three days, and after passage, continue culturing them in a CO2 incubator. Repeat this process until the cell number meets the requirements for in vivo drug efficacy.

[0147] c) Collect cells in the exponential growth phase, count them using an automated cell counter, resuspend them in PBS to 2×10⁷ cells / mL based on the counting results, and place them in an ice box for later use.

[0148] 3.3 Cell Seeding a) Before inoculation, nude mice were marked with disposable universal ear tags for mice and rats.

[0149] b) When inoculating, mix the cell suspension well, draw 0.1-1 mL of cell suspension with a 1 mL syringe, remove air bubbles, and then place the syringe on an ice pack for later use.

[0150] c) Hold the nude mouse firmly with your left hand, and disinfect the right side of the mouse's back near the right shoulder (inoculation site) with a 75% alcohol swab. Begin inoculation after 30 seconds.

[0151] d) Inoculate the nude mice sequentially (0.1 mL of cell suspension per mouse).

[0152] 3.4 Tumor measurement, grouping, and drug administration in tumor-bearing mice a) Based on the tumor growth, measure the tumor and calculate its size on days 9-12 after inoculation.

[0153] Tumor volume calculation: Tumor volume (mm) 3 = Length (mm) × Width (mm) × Width (mm) / 2 b) The mice were randomly assigned to groups based on their weight and tumor size.

[0154] c) Based on the grouping results, begin administering the test drug. Oral administration, with dosage and dosing schedule as shown in the table. The solvent is 0.5% CMC-Na (1% Tween 80).

[0155] d) After starting the test drug, measure and weigh the tumor twice a week.

[0156] e) Euthanize the animals after the experiment.

[0157] f) Process the data using software such as Excel. Calculation of the tumor inhibition rate (TGI) (%): When there is no tumor regression, TGI (%) = [1 - (mean tumor volume at the end of treatment in a certain treatment group - mean tumor volume at the beginning of treatment in that treatment group) / (mean tumor volume at the end of treatment in the solvent control group - mean tumor volume at the beginning of treatment in the solvent control group)] × 100%. When there is tumor regression, TGI (%) = [1 - (mean tumor volume at the end of treatment in a certain treatment group - mean tumor volume at the beginning of treatment in that treatment group) / mean tumor volume at the beginning of treatment in that treatment group] × 100%.

[0158] 4. Experimental Results and Conclusions: Table 5. In vivo efficacy parameters As shown in the table above, the compounds in the examples, when administered orally, significantly inhibited tumor proliferation and caused tumor regression at a dose of 60 mg / kg (BID), indicating that the compounds in the examples have a good inhibitory effect on tumor proliferation.

Claims

1. A compound of general formula (I) or a pharmaceutically acceptable salt thereof: M1 is selected from C, CH, or N; M2 is selected from C, CH, or N; L1 is selected from bond, O, S, or NH; L is selected from bond, C1-C6 alkylene, C 3-8 Cycloalkylene, 3-8 membered heterocyclic alkylene, C1-C6 alkylene-C 3-8 Cycloalkylene or C1-C6 alkylene-3-8-membered heterocyclic alkylene, wherein the C1-C6 alkylene, C 3-8 Cycloalkylene groups and 3-8 membered heterocyclic groups may be replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, or C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Alternatively, two substituents on the same carbon atom in a C1-C6 alkylene group can be linked to form a C1-C6 alkylene group. 3-8 cycloalkyl or 3-8 membered heterocyclic groups, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Ring A is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups; R is selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 aryl or 5-14 heteroaryl groups, wherein the above substituents may optionally be further replaced by 1, 2, 3, 4, 5 or 6 R groups. c replace; R1 is selected from C 6-10 Aryl or 5-10 heteroaryl, wherein the C 6-10 The aryl or 5-10 heteroaryl group can optionally be further divided by 1, 2, 3, 4, 5 or 6 R groups. e replace; R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R b1 Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, -(CR cc R dd ) n1 -C 3-12 cycloalkyl, -(CR cc R dd ) n1 -3-12-membered heterocyclic group, -(CR) cc R dd ) n1 -C 6-14 Aryl, -(CR cc R dd ) n1 -5-14 heteroaryl groups, -(CR cc R dd ) n1 -OR aa 、-(CR cc R dd ) n1 -SR aa 、-(CR cc R dd ) n1 -NR aa R bb 、-(CR cc R dd ) n1 -C(O)R aa 、-(CR cc R dd ) n1 -C(O)NR aa R bb 、-(CR cc R dd ) n1 -C(O)OR aa 、-(CR cc R dd ) n1 -OC(O)R aa 、-(CR cc R dd ) n1 -NR aa C(O)R bb 、-(CR cc R dd ) n1 -P(O)R aa R bb 、-(CR cc R dd ) n1 -S(O) m1 R aa 、-(CR cc R dd ) n1 -NR aa S(O) m1 R bb or -(CR) cc R dd ) n1 -S(O) m1 NR aa R bb The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R b2 Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, -(CR cc R dd ) n1 -C 3-12 cycloalkyl, -(CR cc R dd ) n1 -3-12-membered heterocyclic group, -(CR) cc R dd ) n1 -C 6-14 Aryl, -(CR cc R dd ) n1 -5-14 heteroaryl groups, -(CR cc R dd ) n1 -OR aa 、-(CR cc R dd ) n1 -SR aa 、-(CR cc R dd ) n1 -NR aa R bb 、-(CR cc R dd ) n1 -C(O)R aa 、-(CR cc R dd ) n1 -C(O)NR aa R bb 、-(CR cc R dd ) n1 -C(O)OR aa 、-(CR cc R dd ) n1 -OC(O)R aa 、-(CR cc R dd ) n1 -NR aa C(O)R bb 、-(CR cc R dd ) n1 -P(O)R aa R bb 、-(CR cc R dd ) n1 -S(O) m1 R aa 、-(CR cc R dd ) n1 -NR aa S(O) m1 R bb or -(CR) cc R dd ) n1 -S(O) m1 NR aa R bb The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, R b1 With R b2 The links form a 3-12 member heterocyclic group, which can optionally be further linked by 1, 2, 3, 4, 5 or 6 R groups. b Replacement; preferably forming a 3-8 member monocyclic heterocyclic group, a 7-12 member fused heterocyclic group, a 7-11 member spirocyclic heterocyclic group, or a 7-12 member bridged heterocyclic group, optionally further replaced by 1, 2, 3, 4, 5, or 6 R groups. b replace; R b Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, -(CH2) n1 -C 3-12 Cycloalkyl, -(CH2) n1 -3-12-membered heterocyclic group, -(CH2) n1 -C 6-14 Aryl, -(CH2) n1 -5-14 heteroaryl groups, -(CH2) n1 -OR aa -(CH2) n1 -NR aa R bb -(CH2) n1 -C(O)R aa -(CH2) n1 -C(O)NR aa R bb -(CH2) n1 -NR aa C(O)R bb -(CH2) n1 -S(O) m1 R aa -(CH2) n1 -NR aa S(O) m1 R bb -(CH2) n1 -S(O) m1 NR aa R bb =CR aa R bb The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, any two R b Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic groups, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions in aryl or 5-10 heteroaryl groups; R c Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl, 5-14 heteroaryl, =CR 1a R 1b =NOR 1a or -(CR) 1a R 1b ) n4 ORf, the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, any two R c Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic groups, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions in aryl or 5-10 heteroaryl groups; R e Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl, 5-14 heteroaryl, -OR 5a -NR 5a R 5b =CR 5a R 5b =N-OR 5b -NR 5a C(O)R 5b -P(O)R 5a R 5b -C(O)R 5a -C(O)NR 5a R 5b -S(O) m2 R 5a -S(O) m2 NR 5a R 5b or -S(O) m2 NR 5a R 5b The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl and 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, any two R e Link formation C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl, wherein the C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-10 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R f Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-15 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-15 Deuterated alkyl, C 1-15 Haloalkyl, C 1-15 Alkoxy, C 1-15 Alkylthio, C 1-15 Deuterated alkoxy, C 1-15 Halogenated alkoxy groups, C 1-15 Hydroxyalkyl, C 1-15 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl, 5-14 heteroaryl, -(CR 2a R 2b ) n5 R 2c 、-(CR 2a R 2b ) n5 OR 2c 、-(CR 2a R 2b ) n5 SR 2c 、-(CR 2a R 2b ) n5 NR 2c R 2d 、-(CR 2a R 2b ) n5 P(O)R 2c R 2d 、-(CR 2a R 2b ) n5 C(O)R 2c 、-(CR 2a R 2b ) n5 C(O)NR 2c R 2d 、-(CR 2a R 2b ) n5 NR 2c C(O)R 2d 、-(CR 2a R 2b ) n5 S(O)R 2c 、-(CR 2a R 2b ) n5 S(O)2R 2c 、-(CR 2a R 2b ) n5 S(O)2NR 2c R 2d 、-(CR 2a R 2b ) n5 NR 2c S(O)2R 2d -(CH2CH2O) n5 R 2c Or -CH[CH2O(CH2CH2O) n5 R 2c ]2, the amino group, C 1-15 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-15 Deuterated alkyl, C 1-15 Haloalkyl, C 1-15 Alkoxy, C 1-15 Alkylthio, C 1-15 Deuterated alkoxy, C 1-15 Halogenated alkoxy groups, C 1-15 Hydroxyalkyl, C 1-15 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 1a and R 1b Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, oxo, thio, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, R 1a and R 1b Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic rings, wherein the C 3-8 The cycloalkyl group and 3-8 membered heterocycles may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 2a and R 2b Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, oxo, thio, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, R 2a and R 2b Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic rings, wherein the C 3-8 The cycloalkyl group and 3-8 membered heterocycles may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 2c and R 2d Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, oxo, thio, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-10 heteroaryl, -(CH2) n6 OR 2e and -(CH2) n6 C(O)R 2e One or more substitutions in; Or, R 2c and R 2d Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic rings, wherein the C 3-8 The cycloalkyl group and 3-8 membered heterocycles may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 2e Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 5a and R 5b Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, R 5a and R 5b The linkage forms a 3-8 membered heterocyclic group or a 5-10 membered heteroaryl group, wherein the 3-8 membered heterocyclic group and the 5-10 membered heteroaryl group may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R aa Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R bb Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, R aa and R bb Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic groups, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are selected from aryl, 5-10 heteroaryl, =CH2, =CHF or =CF2; R cc Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R dd Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; a is selected from 0, 1, 2, 3 or 4; n1 is selected from 0, 1, 2, 3 or 4; n4 is selected from 0, 1, 2, 3 or 4; n5 is selected from 0, 1, 2, 3 or 4; n6 is selected from 0, 1, 2, 3 or 4; m1 is selected from 0, 1 or 2; m2 is selected from 0, 1 or 2; and m3 is selected from 0, 1 or 2.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that, L is selected from , or ; R 3a R 3b R 3c and R 3d Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R d Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; d is selected from 0, 1, 2, 3 or 4.

3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that, Further, as shown in general formula (A) or (B): M1 is selected from C, CH, or N; M2 is selected from C, CH, or N; M3 is selected from CR. 4a R 4b or N-OR 4c ; M6 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, -(CH2) n1 -C 3-12 Cycloalkyl, -(CH2) n1 -3-12-membered heterocyclic group, -(CH2) n1 -C 6-14 Aryl, -(CH2) n1 -5-14 membered heteroaryl, or ; L1 is selected from O, S, or NH; O is preferred. Ring A is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups; Ring C is selected from C 3-12 Cycloalkyl or 3-12 membered heterocyclic groups; Ring D is selected from C 3-8 Cycloalkyl or 3-8 membered heterocyclic groups; preferably C 3-6 cycloalkyl; more preferably cyclopropyl; R1 is selected from C 6-10 Aryl or 5-10 heteroaryl, wherein the C 6-10 The aryl or 5-10 heteroaryl group can optionally be further divided by 1, 2, 3, 4, 5 or 6 R groups. e replace; R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 3a R 3b R 3c and R 3d Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 4a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, -(CR cc R dd ) n2 -C 3-12 cycloalkyl, -(CR cc R dd ) n2 -3-12-membered heterocyclic group, -(CR) cc R dd ) n2 -C 6-14 Aryl, -(CR cc R dd ) n2 -5-14 heteroaryl groups, -(CR cc R dd ) n2 -OR ee 、-(CR cc R dd ) n2 -NR ee R ff 、-(CR cc R dd ) n2 -C(O)R ee 、-(CR cc R dd ) n2 -C(O)NR ee R ff 、-(CR cc R dd ) n2 -NR ee C(O)R ff 、-(CR cc R dd ) n2 -S(O) m2 R ee 、-(CR cc R dd ) n2 -NR ee S(O) m2 R ff or -(CR) cc R dd ) n2 -S(O) m2 NR ee R ff The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are selected from aryl and 5-10 heteroaryl groups; preferably hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 4b Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, -(CR cc R dd ) n2 -C 3-12 cycloalkyl, -(CR cc R dd ) n2 -3-12-membered heterocyclic group, -(CR) cc R dd ) n2 -C 6-14 Aryl, -(CR cc R dd ) n2 -5-14 heteroaryl groups, -(CR cc R dd ) n2 -OR ee 、-(CR cc R dd ) n2 -NR ee R ff 、-(CR cc R dd ) n2 -C(O)R ee 、-(CR cc R dd ) n2 -C(O)NR ee R ff 、-(CR cc R dd ) n2 -NR ee C(O)R ff 、-(CR cc R dd ) n2 -S(O) m2 R ee 、-(CR cc R dd ) n2 -NR ee S(O) m2 R ff or -(CR) cc R dd ) n2 -S(O) m2 NR ee R ff The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are selected from aryl and 5-10 heteroaryl groups; preferably hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, R 4a and R 4b Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic groups, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions in aryl or 5-10 heteroaryl groups; R 4c Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, -(CR cc R dd ) n2 -C 3-12 cycloalkyl, -(CR cc R dd ) n2 -3-12-membered heterocyclic group, -(CR) cc R dd ) n2 -C 6-14 Aryl, -(CR cc R dd ) n2 -5-14 heteroaryl groups, -(CR cc R dd ) n2 -OR ee 、-(CR cc R dd ) n2 -NR ee R ff 、-(CR cc R dd ) n2 -C(O)R ee 、-(CR cc R dd ) n2 -C(O)NR ee R ff 、-(CR cc R dd ) n2 -NR ee C(O)R ff 、-(CR cc R dd ) n2 -S(O) m3 R ee 、-(CR cc R dd ) n2 -NR ee S(O) m3 R ff or -(CR) cc R dd ) n2 -S(O) m3 NR ee R ff The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are selected from aryl and 5-10 heteroaryl groups; preferably hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R b1 Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, -(CR cc R dd ) n1 -C 3-12 cycloalkyl, -(CR cc R dd ) n1 -3-12-membered heterocyclic group, -(CR) cc R dd ) n1 -C 6-14 Aryl, -(CR cc R dd ) n1 -5-14 heteroaryl groups, -(CR cc R dd ) n1 -OR aa 、-(CR cc R dd ) n1 -SR aa 、-(CR cc R dd ) n1 -NR aa R bb 、-(CR cc R dd ) n1 -C(O)R aa 、-(CR cc R dd ) n1 -C(O)NR aa R bb 、-(CR cc R dd ) n1 -C(O)OR aa 、-(CR cc R dd ) n1 -OC(O)R aa 、-(CR cc R dd ) n1 -NR aa C(O)R bb 、-(CR cc R dd ) n1 -P(O)R aa R bb 、-(CR cc R dd ) n1 -S(O) m1 R aa 、-(CR cc R dd ) n1 -NR aa S(O) m1 R bb or -(CR) cc R dd ) n1 -S(O) m1 NR aa R bb The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are selected from aryl and 5-10 heteroaryl groups; preferably from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, -(CH2) n1 -C 3-12 Cycloalkyl, -(CH2) n1 -3-12-membered heterocyclic group, -(CH2) n1 -C 6-14 Aryl, -(CH2) n1 -5-14 heteroaryl groups, -(CH2) n1 -OR aa -(CH2) n1 -NR aa R bb -(CH2) n1 -C(O)R aa -(CH2) n1 -C(O)NR aa R bb -(CH2) n1 -NR aa C(O)R bb -(CH2) n1 -S(O) m1 R aa -(CH2) n1 -NR aa S(O) m1 R bb Or -(CH2) n1 -S(O) m1 NR aa R bb The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R b2 Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, -(CR cc R dd ) n1 -C 3-12 cycloalkyl, -(CR cc R dd ) n1 -3-12-membered heterocyclic group, -(CR) cc R dd ) n1 -C 6-14 Aryl, -(CR cc R dd ) n1 -5-14 heteroaryl groups, -(CR cc R dd ) n1 -OR aa 、-(CR cc R dd ) n1 -SR aa 、-(CR cc R dd ) n1 -NR aa R bb 、-(CR cc R dd ) n1 -C(O)R aa 、-(CR cc R dd ) n1 -C(O)NR aa R bb 、-(CR cc R dd ) n1 -C(O)OR aa 、-(CR cc R dd ) n1 -OC(O)R aa 、-(CR cc R dd ) n1 -NR aa C(O)R bb 、-(CR cc R dd ) n1 -P(O)R aa R bb 、-(CR cc R dd ) n1 -S(O) m1 R aa 、-(CR cc R dd ) n1 -NR aa S(O) m1 R bb or -(CR) cc R dd ) n1 -S(O) m1 NR aa R bb The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are selected from aryl and 5-10 heteroaryl groups; preferably from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, -(CH2) n1 -C 3-12 Cycloalkyl, -(CH2) n1 -3-12-membered heterocyclic group, -(CH2) n1 -C 6-14 Aryl, -(CH2) n1 -5-14 heteroaryl groups, -(CH2) n1 -OR aa -(CH2) n1 -NR aa R bb -(CH2) n1 -C(O)R aa -(CH2) n1 -C(O)NR aa R bb -(CH2) n1 -NR aa C(O)R bb -(CH2) n1 -S(O) m1 R aa -(CH2) n1 -NR aa S(O) m1 R bb Or -(CH2) n1 -S(O) m1 NR aa R bb The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, R b1 With R b2 The links form a 3-12 member heterocyclic group, which can optionally be further linked by 1, 2, 3, 4, 5 or 6 R groups. b Replacement; preferably forming a 3-8 member monocyclic heterocyclic group, a 7-12 member fused heterocyclic group, a 7-11 member spirocyclic heterocyclic group, or a 7-12 member bridged heterocyclic group, optionally further replaced by 1, 2, 3, 4, 5, or 6 R groups. b replace; R b Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, -(CH2) n1 -C 3-12 Cycloalkyl, -(CH2) n1 -3-12-membered heterocyclic group, -(CH2) n1 -C 6-14 Aryl, -(CH2) n1 -5-14 heteroaryl groups, -(CH2) n1 -OR aa -(CH2) n1 -NR aa R bb -(CH2) n1 -C(O)R aa -(CH2) n1 -C(O)NR aa R bb -(CH2) n1 -NR aa C(O)R bb -(CH2) n1 -S(O) m1 R aa -(CH2) n1 -NR aa S(O) m1 R bb Or -(CH2) n1 -S(O) m1 NR aa R bb The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, any two R b Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic groups, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions in aryl or 5-10 heteroaryl groups; R c Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl, 5-14 quinone heteroaryl or -(CR 1a R 1b ) n4 ORf, the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are selected from aryl and 5-10 heteroaryl groups; preferably from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, any two R c Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic groups, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions in aryl or 5-10 heteroaryl groups; R d Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R e Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl, 5-14 heteroaryl, -OR 5a -NR 5a R 5b =CR 5a R 5b =N-OR 5b -NR 5a C(O)R 5b -P(O)R 5a R 5b -C(O)R 5a -C(O)NR 5a R 5b -S(O) m2 R 5a -S(O) m2 NR 5a R 5b or -S(O) m2 NR 5a R 5b The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl and 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are made from aryl and 5-10 heteroaryl groups; preferably hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl, 5-14 heteroaryl, -OR 5a -NR 5a R 5b -NR 5a C(O)R 5b -P(O)R 5a R 5b -C(O)R 5a -C(O)NR 5a R 5b -S(O) m2 R 5a -S(O) m2 NR 5a R 5b or -S(O) m2 NR 5a R 5b The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl and 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, any two R e Link formation C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl, wherein the C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-10 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R f Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-15 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-15 Deuterated alkyl, C 1-15 Haloalkyl, C 1-15 Alkoxy, C 1-15 Alkylthio, C 1-15 Deuterated alkoxy, C 1-15 Halogenated alkoxy groups, C 1-15 Hydroxyalkyl, C 1-15 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl, 5-14 heteroaryl, -(CR 2a R 2b ) n5 R 2c 、-(CR 2a R 2b ) n5 OR 2c 、-(CR 2a R 2b ) n5 SR 2c 、-(CR 2a R 2b ) n5 NR 2c R 2d 、-(CR 2a R 2b ) n5 P(O)R 2c R 2d 、-(CR 2a R 2b ) n5 C(O)R 2c 、-(CR 2a R 2b ) n5 C(O)NR 2c R 2d 、-(CR 2a R 2b ) n5 NR 2c C(O)R 2d 、-(CR 2a R 2b ) n5 S(O)R 2c 、-(CR 2a R 2b ) n5 S(O)2R 2c 、-(CR 2a R 2b ) n5 S(O)2NR 2c R 2d 、-(CR 2a R 2b ) n5 NR 2c S(O)2R 2d -(CH2CH2O) n5 R 2c Or -CH[CH2O(CH2CH2O) n5 R 2c ]2, the amino group, C 1-15 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-15 Deuterated alkyl, C 1-15 Haloalkyl, C 1-15 Alkoxy, C 1-15 Alkylthio, C 1-15 Deuterated alkoxy, C 1-15 Halogenated alkoxy groups, C 1-15 Hydroxyalkyl, C 1-15 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 1a and R 1b Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, oxo, thio, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, R 1a and R 1b Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic rings, wherein the C 3-8 The cycloalkyl group and 3-8 membered heterocycles may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 2a and R 2b Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, oxo, thio, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, R 2a and R 2b Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic rings, wherein the C 3-8 The cycloalkyl group and 3-8 membered heterocycles may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 2c and R 2d Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, oxo, thio, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-10 heteroaryl, -(CH2) n6 OR 2e and -(CH2) n6 C(O)R 2e One or more substitutions in; Or, R 2c and R 2d Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic rings, wherein the C 3-8 The cycloalkyl group and 3-8 membered heterocycles may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 2e Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 5a and R 5b Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, R 5a and R 5b The linkage forms a 3-8 membered heterocyclic group or a 5-10 membered heteroaryl group, wherein the 3-8 membered heterocyclic group and the 5-10 membered heteroaryl group may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R aa Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R bb Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, R aa and R bb Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic groups, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions in aryl or 5-10 heteroaryl groups; R cc Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R dd Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R ee Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R ff Selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, R ee and R ff The linker forms a 3-12 membered heterocyclic group, which may optionally be further coupled with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, or C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are selected from aryl, 5-10 heteroaryl, =CH2, =CHF or =CF2; a is selected from 0, 1, 2, 3, or 4; c is selected from 0, 1, 2, 3, or 4; d is selected from 0, 1, 2, 3, or 4; n1 is selected from 0, 1, 2, 3, or 4; n2 is selected from 0, 1, 2, 3, or 4; n4 is selected from 0, 1, 2, 3, or 4; n5 is selected from 0, 1, 2, 3, or 4; n6 is selected from 0, 1, 2, 3, or 4; m2 is selected from 0, 1, or 2; and m3 is selected from 0, 1, or 2.

4. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, characterized in that, R b1 Selected from , 、-(CR cc R dd ) n1 -OR aa 、-(CR cc R dd ) n1 -SR aa 、-(CR cc R dd ) n1 -NR aa R bb 、-(CR cc R dd ) n1 -C(O)R aa 、-(CR cc R dd ) n1 -C(O)NR aa R bb 、-(CR cc R dd ) n1 -C(O)OR aa 、-(CR cc R dd ) n1 -NR aa C(O)R bb 、-(CR cc R dd ) n1 -P(O)R aa R bb 、-(CR cc R dd ) n1 -S(O) m1 R aa 、-(CR cc R dd ) n1 -NR aa S(O) m1 R bb or -(CR) cc R dd ) n1 -S(O) m1 NR aa R bb The C mentioned 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; preferably from 、-(CR cc R dd ) n1 -OR aa 、-(CR cc R dd ) n1 -SR aa 、-(CR cc R dd ) n1 -NR aa R bb 、-(CR cc R dd ) n1 -C(O)R aa 、-(CR cc R dd ) n1 -C(O)NR aa R bb 、-(CR cc R dd ) n1 -C(O)OR aa 、-(CR cc R dd ) n1 -NR aa C(O)R bb 、-(CR cc R dd ) n1 -P(O)R aa R bb 、-(CR cc R dd ) n1 -S(O) m1 R aa 、-(CR cc R dd ) n1 -NR aa S(O) m1 R bb or -(CR) cc R dd ) n1 -S(O) m1 NR aa R bb The C mentioned 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; more preferably ; R b2 Selected from hydrogen, C 1-6 Alkyl, C 1-6 Deuterated alkyl or C 1-6 Halogenated alkyl groups, optionally further reacted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; preferably from hydrogen, C 1-6 Alkyl, C 1-6 Deuterated alkyl or C 1-6 Halogenated alkyl groups; Ring B is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups; b is selected from 0, 1, 2, 3, or 4; R b As defined in claim 1; Alternatively, M1 is selected from C or N; C is preferred. Alternatively, M2 is selected from C or N; C is preferred. Alternatively, ring A is selected from C. 3-8 Cycloalkyl, 3-8 membered heterocyclic or 5-6 membered heteroaryl; The following groups are preferred: , , , , , , , , , , , or .

5. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, characterized in that, Further, as shown in general formulas (A-1), (A-2), (B-1), or (B-2): L2 is selected from the key or C. 1-4 Alkylene, the C 1-4 Alkyl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, or C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; L3 is selected from bond, -O-, -C(O)-, -S(O)2-, -NR 6a -, -C(O)O-, -OC(O)-, -C(O)NR 6a -、-NR 6a C(O)-、-S(O)2NR 6a -or-NR 6a S(O)2-; L4 is selected from the bond, C(O) or C 1-4 Alkylene, the C 1-4 Alkyl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, or C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R g Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 6a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; c-1 is selected from 0, 1, 2 or 3; f is selected from 0, 1 or 2.

6. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, characterized in that, R 4a Selected from hydrogen, deuterium, halogen, cyano, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, -(CR cc R dd ) n2 -C 3-8 cycloalkyl, -(CR cc R dd ) n2 -3-8 membered heterocyclic group, -(CR cc R dd ) n2 -OR ee 、-(CR cc R dd ) n2 -NR ee R ff 、-(CR cc R dd ) n2 -C(O)R ee 、-(CR cc R dd ) n2 -C(O)NR ee R ff 、-(CR cc R dd ) n2 -NR ee C(O)R ff 、-(CR cc R dd ) n2 -S(O) m2 R ee 、-(CR cc R dd ) n2 -NR ee S(O) m2 R ff or -(CR) cc R dd ) n2 -S(O) m2 NR ee R ff The C mentioned 1-3 Alkyl C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; preferably hydrogen, deuterium, halogen, cyano, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 3-8 cycloalkyl or 3-8 membered heterocyclic groups, wherein the C 1-3 Alkyl C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are made of aryl and 5-10 heteroaryl groups; more preferably hydrogen, deuterium, fluorine, chlorine, bromine, methyl, ethyl, deuterated methyl, deuterated ethyl, halomethyl, haloethyl or cyclopropyl. R 4b Selected from hydrogen, deuterium, halogen, cyano, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 3-8 cycloalkyl or 3-8 membered heterocyclic groups, wherein the C 1-3 Alkyl C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are made from aryl and 5-10 heteroaryl groups; preferably hydrogen, deuterium, fluorine, chlorine, bromine, methyl, ethyl, deuterated methyl, deuterated ethyl, halomethyl, haloethyl or cyclopropyl. Or, R 4c Selected from hydrogen, deuterium, halogen, cyano, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, -(CR cc R dd ) n2 -C 3-8 cycloalkyl, -(CR cc R dd ) n2 -3-8 membered heterocyclic group, -(CR cc R dd ) n2 -OR ee 、-(CR cc R dd ) n2 -NR ee R ff 、-(CR cc R dd ) n2 -C(O)R ee 、-(CR cc R dd ) n2 -C(O)NR ee R ff 、-(CR cc R dd ) n2 -NR ee C(O)R ff 、-(CR cc R dd ) n2 -S(O) m2 R ee 、-(CR cc R dd ) n2 -NR ee S(O) m2 R ff or -(CR) cc R dd ) n2 -S(O) m2 NR ee R ff The C mentioned 1-3 Alkyl C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; preferably C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 3-8 cycloalkyl or 3-8 membered heterocyclic groups, wherein the C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are made of aryl and 5-10 heteroaryl groups; more preferably methyl, ethyl, deuterated methyl, deuterated ethyl, halomethyl, haloethyl, cyclopropyl or cyclopropylmethyl. Alternatively, R or ring C is selected from 3-8 member monocyclic heterocyclic groups, 7-10 member fused heterocyclic groups, 7-11 member spirocyclic groups or 7-10 member bridged heterocyclic groups; The following groups are preferred: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or ; More preferably, the following groups are preferred: , , , , , , , , , , , , , , , , , , , , , , , , , , , or .

7. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6, characterized in that, R d Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl or C 1-3 Alkylamino, the amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl and C 1-3 Alkylamino groups can optionally be further modified by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, or C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are made from aryl and 5-10 heteroaryl groups; preferably hydrogen, deuterium, fluorine, chlorine, bromine, amino, nitro, hydroxyl, cyano, methyl, ethyl, deuterated methyl, deuterated ethyl, halomethyl or haloethyl; Or, R 3a R 3b R 3c and R 3d Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy or C 1-3 Hydroxyalkyl; Preferably R 3a Selected from hydrogen or deuterium; R 3b Selected from hydrogen or deuterium; R 3c Selected from hydrogen or deuterium; R 3d Selected from hydrogen or deuterium; Alternatively, R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl or C 1-3 Alkylamino; preferably, R2 is selected from hydrogen, deuterium, fluorine, chlorine or bromine; more preferably, R2 is selected from fluorine.

8. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, characterized in that, Ring B is selected from C 3-8 cycloalkyl, C 7-12 Fused cycloalkyl, 3-8 membered monocyclic heterocyclic group, 7-12 membered fused heterocyclic group, 7-11 membered spirocyclic group, 7-12 membered bridged heterocyclic group or 5-10 membered heteroaryl group; Preferably, it is derived from 3-8 member monocyclic heterocyclic groups, 7-12 member fused heterocyclic groups, 7-11 member spiroheterocyclic groups, or 7-12 member bridged heterocyclic groups; More preferably, the following groups are preferred: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or ; Further preferred groups include: , , , , , , , , , , , , , , or ; Or, R b Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, -(CH2) n1 -C 3-8 Cycloalkyl, -(CH2) n1 -3-8 membered heterocyclic group, -(CH2) n1 -C 6-10 Aryl, -(CH2) n1 -5-10 heteroaryl groups, -(CH2) n1 -OR aa -(CH2) n1 -NR aa R bb -(CH2) n1 -C(O)R aa -(CH2) n1 -C(O)NR aa R bb -(CH2) n1 - NR aa C(O)R bb -(CH2) n1 -S(O) m1 R aa -(CH2) n1 -NR aa S(O) m1 R bb -(CH2) n1 -S(O) m1 NR aa R bb or =CR aa R bb The amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl and C 1-3 Alkylamino groups can optionally be further modified by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, or C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are selected from aryl and 5-10 heteroaryl groups; preferably from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, -(CH2) n1 -C 3-8 Cycloalkyl, -(CH2) n1 -3-8 membered heterocyclic group, -(CH2) n1 -C 6-10 Aryl, -(CH2) n1 -5-10 heteroaryl groups, -(CH2) n1 -OR aa -(CH2) n1 -NR aa R bb -(CH2) n1 -C(O)R aa -(CH2) n1 -C(O)NR aa R bb -(CH2) n1 - NR aa C(O)R bb -(CH2) n1 -S(O) m1 R aa -(CH2) n1 -NR aa S(O) m1 R bb Or -(CH2) n1 -S(O) m1 NR aa R bb The amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl and C 1-3 Alkylamino groups can optionally be further modified by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, or C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, R a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl or C 1-3 Alkylamino, the amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl and C 1-3 Alkylamino groups can optionally be further modified by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, or C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; The preferred radicals are hydrogen, deuterium, fluorine, chlorine, bromine, amino, nitro, hydroxyl, cyano, methyl, ethyl, deuterated methyl, deuterated ethyl, halomethyl, or haloethyl.

9. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8, characterized in that, R1 is selected from , , or Preferred , or ; M9 is selected from CR 6-5 Or N; M4 is selected from CR 7-1 Or N; M5 is selected from CR 8-2 Or N; Preferably, R1 is selected from , , , , , , , , , , , , , , , , , , , , , or ; Preferably, R1 is selected from , , , , , , , , , or ; R 5-1 R 5-2 R 5-3 R 5-4 R 5-5 R 5-6 and R 5-7 Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-10 heteroaryl, -OR 5a -NR 5a R 5b -NR 5a C(O)R 5b -P(O)R 5a R 5b -C(O)R 5a -C(O)NR 5a R 5b -S(O) m2 R 5a -S(O) m2 NR 5a R 5b or -S(O) m2 NR 5a R 5b The amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are made from aryl and 5-10 heteroaryl groups; preferably hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl, wherein the amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 6-1 R 6-2 R 6-3 R 6-4 and R 6-5 Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-10 heteroaryl, -OR 5a -NR 5a R 5b -NR 5a C(O)R 5b -P(O)R 5a R 5b -C(O)R 5a -C(O)NR 5a R 5b -S(O) m2 R 5a -S(O) m2 NR 5a R 5b or -S(O) m2 NR 5a R 5b The amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are made from aryl and 5-10 heteroaryl groups; preferably hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl, wherein the amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 7-1 R 7-2 R 7-3 R 7-4 and R 7-5 Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-10 heteroaryl, -OR 5a -NR 5a R 5b -NR 5a C(O)R 5b -P(O)R 5a R 5b -C(O)R 5a -C(O)NR 5a R 5b -S(O) m2 R 5a -S(O) m2 NR 5a R 5b or -S(O) m2 NR 5a R 5b The amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are made from aryl and 5-10 heteroaryl groups; preferably hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl, wherein the amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R 8-1 Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl, 5-14 heteroaryl, -OR 5a -NR 5a R 5b =CR 5a R 5b =N-OR 5b -NR 5a C(O)R 5b -P(O)R 5a R 5b -C(O)R 5a -C(O)NR 5a R 5b -S(O) m2 R 5a -S(O) m2 NR 5a R 5b or -S(O) m2 NR 5a R 5b The amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl and 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are made from aryl and 5-10 heteroaryl groups; preferably hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-14 Aryl or 5-14 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; Or, any two R 8-1 Link formation C 3-8 cycloalkyl or 3-8 membered heterocyclic groups, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocyclic groups may optionally be further replaced by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl or 5-10 heteroaryl groups R 8-2 R 8-3 and R 8-4 Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-10 heteroaryl, -OR 5a -NR 5a R 5b -NR 5a C(O)R 5b -P(O)R 5a R 5b -C(O)R 5a -C(O)NR 5a R 5b -S(O) m2 R 5a -S(O) m2 NR 5a R 5b or -S(O) m2 NR 5a R 5b The amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions are made from aryl and 5-10 heteroaryl groups; preferably hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl, wherein the amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; n3 is selected from 0, 1, or 2; and u is selected from 0, 1, 2, 3, 4, 5, or 6.

10. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9, characterized in that, Further, as shown in general formulas (A-1-1), (B-1-1), or (B-1-2): M7 is selected from C, CH or N; preferably C or N; M8 is selected from C, CH or N; preferably C or N; Ring F is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl groups; R m Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl, wherein the amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; R n Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl, wherein the amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Deuterated alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Hydroxyalkyl, C 1-3 Alkylamino, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl groups may optionally be further converted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, oxo, thio, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, -C(O)-C 1-6 Alkyl, -C(O)OC 1-6 Alkyl, C 1-6 Silyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic groups, C 6-10 One or more substitutions of aryl and 5-10 heteroaryl groups; m is selected from 0, 1, 2, 3, 4 or 5; n is selected from 0, 1, 2, 3, 4 or 5; n8 is selected from 0, 1, 2 or 3; n9 is selected from 0, 1, 2 or 3; n10 is selected from 0, 1, 2 or 3.

11. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10, characterized in that, Selected from the following compounds: or .

12. A method for preparing a compound of general formula (A-1-1), its stereoisomers, or pharmaceutically acceptable salts thereof, comprising the following step 1: The compound of general formula (A-1-2) reacts with the compound of general formula (A-1-3) under alkaline conditions to give the compound of general formula (A-1-1); Optionally, step 2 may be further included: R L1 Selected from halogens; preferably chlorine or bromine; R L2 Selected from borate group, borate group, chain borate ester group or cyclic borate ester group; R L3 Selected from halogens, hydroxyl groups, or -S(O). m2 -C 1-3 Alkyl group; preferably chlorine, bromine, -S(O)-CH3 or -S(O)2-CH3; m2 is selected from 0, 1, or 2; R a R2, R b2 and a as defined in claim 1; R d and d as defined in claim 2; R c M3 and c as defined in claim 3; rings B and R b b and n1 as defined in claim 4; M9, R 6-1 ~R 6-5 As defined in claim 9; n8 and n9 as defined in claim 10.

13. A pharmaceutical composition comprising a therapeutically effective dose of any of the compounds shown in claims 1 to 11 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients.

14. The use of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 11, or the pharmaceutical composition of claim 13, in the preparation of a KRAS inhibitor medicament; preferably in the preparation of a KRAS G12C, KRAS G12D, KRAS G12V, KRAS G12S, or KRAS G13D inhibitor medicament.

15. The use of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 11, or the pharmaceutical composition of claim 13, in the preparation of a medicament for treating diseases or conditions such as Noonan syndrome, panther syndrome, leukemia, neuroblastoma, melanoma, esophageal cancer, head and neck tumors, breast cancer, lung cancer, pancreatic cancer, and colorectal cancer; preferably, in the preparation of a medicament for treating non-small cell lung cancer, pancreatic cancer, colon cancer, esophageal cancer, and head and neck tumors.

Images